<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Microbiol</journal-id><journal-id journal-id-type="iso-abbrev">Front Microbiol</journal-id><journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id><journal-title-group><journal-title>Frontiers in Microbiology</journal-title></journal-title-group><issn pub-type="epub">1664-302X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6927920</article-id><article-id pub-id-type="doi">10.3389/fmicb.2019.02862</article-id><article-categories><subj-group subj-group-type="heading"><subject>Microbiology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Functional Characterization and Direct Comparison of Influenza A, B, C, and D NS1 Proteins <italic>in vitro</italic> and <italic>in vivo</italic></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nogales</surname><given-names>Aitor</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/602727/overview"/></contrib><contrib contrib-type="author"><name><surname>Aydillo</surname><given-names>Teresa</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/814739/overview"/></contrib><contrib contrib-type="author"><name><surname>&#x000c1;vila-P&#x000e9;rez</surname><given-names>Gines</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/847818/overview"/></contrib><contrib contrib-type="author"><name><surname>Escalera</surname><given-names>Alba</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chiem</surname><given-names>Kevin</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cadagan</surname><given-names>Richard</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>DeDiego</surname><given-names>Marta L.</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Feng</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/143149/overview"/></contrib><contrib contrib-type="author"><name><surname>Garc&#x000ed;a-Sastre</surname><given-names>Adolfo</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff7"><sup>7</sup></xref><xref ref-type="aff" rid="aff8"><sup>8</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/476313/overview"/></contrib><contrib contrib-type="author"><name><surname>Mart&#x000ed;nez-Sobrido</surname><given-names>Luis</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/340837/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Microbiology and Immunology, School of Medicine and Dentistry, University of Rochester</institution>, <addr-line>Rochester, NY</addr-line>, <country>United States</country></aff><aff id="aff2"><sup>2</sup><institution>Centro de Investigaci&#x000f3;n en Sanidad Animal</institution>, <addr-line>Madrid</addr-line>, <country>Spain</country></aff><aff id="aff3"><sup>3</sup><institution>Department of Microbiology, Icahn School of Medicine at Mount Sinai</institution>, <addr-line>New York, NY</addr-line>, <country>United States</country></aff><aff id="aff4"><sup>4</sup><institution>Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai</institution>, <addr-line>New York, NY</addr-line>, <country>United States</country></aff><aff id="aff5"><sup>5</sup><institution>Department of Molecular and Cell Biology, Centro Nacional de Biotecnolog&#x000ed;a, Consejo Superior de Investigaciones Cient&#x000ed;ficas</institution>, <addr-line>Madrid</addr-line>, <country>Spain</country></aff><aff id="aff6"><sup>6</sup><institution>Department of Veterinary and Biomedical Sciences, South Dakota State University</institution>, <addr-line>Brookings, SD</addr-line>, <country>United States</country></aff><aff id="aff7"><sup>7</sup><institution>Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai</institution>, <addr-line>New York, NY</addr-line>, <country>United States</country></aff><aff id="aff8"><sup>8</sup><institution>The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai</institution>, <addr-line>New York, NY</addr-line>, <country>United States</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Patricia V. Aguilar, University of Texas Medical Branch at Galveston, United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: Olivier Terrier, UMR 5308 Centre International de Recherche en Infectiologie (CIRI), France; Daniel Marc, INRA Centre Val de Loire, France</p></fn><corresp id="c001">*Correspondence: Luis Mart&#x000ed;nez-Sobrido, <email>luis_martinez@urmc.rochester.edu</email></corresp><fn fn-type="other" id="fn002"><p><sup>&#x02020;</sup>These authors have contributed equally to this work</p></fn><fn fn-type="other" id="fn004"><p>This article was submitted to Virology, a section of the journal Frontiers in Microbiology</p></fn></author-notes><pub-date pub-type="epub"><day>17</day><month>12</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>10</volume><elocation-id>2862</elocation-id><history><date date-type="received"><day>20</day><month>9</month><year>2019</year></date><date date-type="accepted"><day>26</day><month>11</month><year>2019</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2019 Nogales, Aydillo, &#x000c1;vila-P&#x000e9;rez, Escalera, Chiem, Cadagan, DeDiego, Li, Garc&#x000ed;a-Sastre and Mart&#x000ed;nez-Sobrido.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Nogales, Aydillo, &#x000c1;vila-P&#x000e9;rez, Escalera, Chiem, Cadagan, DeDiego, Li, Garc&#x000ed;a-Sastre and Mart&#x000ed;nez-Sobrido</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Influenza viruses are important pathogens that affect multiple animal species, including humans. There are four types of influenza viruses: A, B, C, and D (IAV, IBV, ICV, and IDV, respectively). IAV and IBV are currently circulating in humans and are responsible of seasonal epidemics (IAV and IBV) and occasional pandemics (IAV). ICV is known to cause mild infections in humans and pigs, while the recently identified IDV primarily affect cattle and pigs. Influenza non-structural protein 1 (NS1) is a multifunctional protein encoded by the NS segment in all influenza types. The main function of NS1 is to counteract the host antiviral defense, including the production of interferon (IFN) and IFN-stimulated genes (ISGs), and therefore is considered an important viral pathogenic factor. Despite of homologous functions, the NS1 protein from the diverse influenza types share little amino acid sequence identity, suggesting possible differences in their mechanism(s) of action, interaction(s) with host factors, and contribution to viral replication and/or pathogenesis. In addition, although the NS1 protein of IAV, IBV and, to some extent ICV, have been previously studied, it is unclear if IDV NS1 has similar properties. Using an approach that allow us to express NS1 independently of the nuclear export protein from the viral NS segment, we have generated recombinant IAV expressing IAV, IBV, ICV, and IDV NS1 proteins. Although recombinant viruses expressing heterotypic (IBV, ICV, and IDV) NS1 proteins were able to replicate similarly in canine MDCK cells, their viral fitness was impaired in human A549 cells and they were highly attenuated <italic>in vivo</italic>. Our data suggest that despite the similarities to effectively counteract innate immune responses <italic>in vitro</italic>, the NS1 proteins of IBV, ICV, or IDV do not fully complement the functions of IAV NS1, resulting in deficient viral replication and pathogenesis <italic>in vivo</italic>.</p></abstract><kwd-group><kwd>influenza A virus (IAV)</kwd><kwd>influenza B virus (IBV)</kwd><kwd>influenza C virus (ICV)</kwd><kwd>influenza D virus (IDV)</kwd><kwd>non-structural protein 1 (NS1)</kwd><kwd>signal transducer and activator of transcription 2 (STAT2)</kwd><kwd>innate immunity</kwd><kwd>interferon (IFN)</kwd></kwd-group><counts><fig-count count="7"/><table-count count="0"/><equation-count count="0"/><ref-count count="117"/><page-count count="16"/><word-count count="0"/></counts></article-meta></front><body><sec id="S1"><title>Introduction</title><p>Influenza viruses belong to the <italic>Orthomyxoviridae</italic> family and are enveloped viruses which contain a segmented genome of single-stranded RNA molecules of negative polarity (<xref rid="B114" ref-type="bibr">Wright et al., 2007</xref>; <xref rid="B73" ref-type="bibr">Nogales and Martinez-Sobrido, 2016</xref>; <xref rid="B51" ref-type="bibr">Martinez-Sobrido et al., 2018</xref>; <xref rid="B5" ref-type="bibr">Blanco-Lobo et al., 2019</xref>). Currently, there are four recognized influenza virus types: A, B, C, and D (IAV, IBV, ICV, and IDV, respectively) (<xref rid="B114" ref-type="bibr">Wright et al., 2007</xref>; <xref rid="B12" ref-type="bibr">Chen and Holmes, 2008</xref>; <xref rid="B112" ref-type="bibr">Wanitchang et al., 2012</xref>; <xref rid="B104" ref-type="bibr">Tong et al., 2013</xref>; <xref rid="B4" ref-type="bibr">Baker et al., 2014</xref>; <xref rid="B115" ref-type="bibr">Yoon et al., 2014</xref>; <xref rid="B36" ref-type="bibr">Hengrung et al., 2015</xref>; <xref rid="B53" ref-type="bibr">Matsuzaki et al., 2016</xref>; <xref rid="B110" ref-type="bibr">Wang et al., 2016</xref>; <xref rid="B24" ref-type="bibr">Foni et al., 2017</xref>; <xref rid="B69" ref-type="bibr">Nogales et al., 2017c</xref>; <xref rid="B101" ref-type="bibr">Su et al., 2017</xref>; <xref rid="B62" ref-type="bibr">Nakatsu et al., 2018</xref>; <xref rid="B1" ref-type="bibr">Asha and Kumar, 2019</xref>; <xref rid="B117" ref-type="bibr">Zhang et al., 2019</xref>). IAV and IBV contain eight genomic viral (v)RNA segments (<xref rid="B114" ref-type="bibr">Wright et al., 2007</xref>), and two major glycoproteins in the virion surface, the hemagglutinin (HA) and neuraminidase (NA), which are responsible for viral binding and release, respectively, of the virus from infected cells (<xref rid="B114" ref-type="bibr">Wright et al., 2007</xref>). Moreover, HA and NA glycoproteins are also the major antigenic determinants of IAV and IBV and they are used to further classify them in subtypes (IAV) or lineages (IBV) (<xref rid="B51" ref-type="bibr">Martinez-Sobrido et al., 2018</xref>; <xref rid="B5" ref-type="bibr">Blanco-Lobo et al., 2019</xref>). IAV have a broad species tropism, infecting multiple avian and mammalian species, including humans (<xref rid="B82" ref-type="bibr">Parrish et al., 2015</xref>; <xref rid="B57" ref-type="bibr">Mostafa et al., 2018</xref>; <xref rid="B46" ref-type="bibr">Long et al., 2019</xref>), while IBV are primarily limited to infect humans (<xref rid="B79" ref-type="bibr">Osterhaus et al., 2000</xref>; <xref rid="B12" ref-type="bibr">Chen and Holmes, 2008</xref>; <xref rid="B86" ref-type="bibr">Piepenbrink et al., 2019</xref>). IAV and IBV are both responsible of seasonal epidemics in the human population and are considered a major public health and economic concern worldwide (<xref rid="B42" ref-type="bibr">Krammer et al., 2015</xref>; <xref rid="B90" ref-type="bibr">Raviotta et al., 2017</xref>; <xref rid="B21" ref-type="bibr">Federici et al., 2018</xref>; <xref rid="B84" ref-type="bibr">Paules et al., 2018</xref>). In contrast, the genome of ICV and IDV is made of seven vRNA segments, since the functions of the HA and the NA glycoproteins in IAV and IBV are combined in the hemagglutinin-esterase-fusion (HEF) glycoprotein of ICV and IDV (<xref rid="B36" ref-type="bibr">Hengrung et al., 2015</xref>; <xref rid="B53" ref-type="bibr">Matsuzaki et al., 2016</xref>; <xref rid="B110" ref-type="bibr">Wang et al., 2016</xref>; <xref rid="B62" ref-type="bibr">Nakatsu et al., 2018</xref>; <xref rid="B1" ref-type="bibr">Asha and Kumar, 2019</xref>; <xref rid="B117" ref-type="bibr">Zhang et al., 2019</xref>). ICV causes mild respiratory illness in humans and pigs and is not thought to cause epidemics (<xref rid="B53" ref-type="bibr">Matsuzaki et al., 2016</xref>). On the other hand, IDV principally affects cattle and pigs and, to date, IDV is not known to infect humans (<xref rid="B24" ref-type="bibr">Foni et al., 2017</xref>; <xref rid="B101" ref-type="bibr">Su et al., 2017</xref>; <xref rid="B1" ref-type="bibr">Asha and Kumar, 2019</xref>). Concerns associated with influenza virus are further exacerbated by their ability to efficiently transmit by the respiratory route and the limited antiviral therapeutic options for their treatment (<xref rid="B59" ref-type="bibr">Munster et al., 2009</xref>; <xref rid="B98" ref-type="bibr">Steel et al., 2009a</xref>; <xref rid="B96" ref-type="bibr">Seibert et al., 2010</xref>; <xref rid="B39" ref-type="bibr">Kimble et al., 2011</xref>; <xref rid="B37" ref-type="bibr">Herfst et al., 2012</xref>; <xref rid="B25" ref-type="bibr">Fouchier et al., 2013</xref>; <xref rid="B113" ref-type="bibr">Watanabe and Kawaoka, 2015</xref>; <xref rid="B13" ref-type="bibr">Cheng and Subbarao, 2018</xref>; <xref rid="B21" ref-type="bibr">Federici et al., 2018</xref>; <xref rid="B76" ref-type="bibr">Nogales et al., 2018c</xref>; <xref rid="B84" ref-type="bibr">Paules et al., 2018</xref>).</p><p>Host innate immune responses activated upon infection, limit viral replication and dissemination (<xref rid="B89" ref-type="bibr">Randall and Goodbourn, 2008</xref>; <xref rid="B10" ref-type="bibr">Carrero, 2013</xref>; <xref rid="B75" ref-type="bibr">Nogales et al., 2018b</xref>). Consequently, viruses have developed multiple mechanisms to counteract the host antiviral responses, especially the induction of interferon (IFN) and the activities of IFN-stimulated gene (ISG) proteins that restrict virus replication (<xref rid="B109" ref-type="bibr">Wang et al., 2007</xref>; <xref rid="B89" ref-type="bibr">Randall and Goodbourn, 2008</xref>; <xref rid="B38" ref-type="bibr">Iwasaki and Pillai, 2014</xref>; <xref rid="B75" ref-type="bibr">Nogales et al., 2018b</xref>). Influenza virus non-structural protein 1 (NS1) is a multifunctional protein, but one of its major and conserved function relates to its ability to inhibit host innate immunity, allowing efficient viral replication in IFN-competent systems (<xref rid="B26" ref-type="bibr">Garcia-Sastre et al., 1998</xref>; <xref rid="B102" ref-type="bibr">Talon et al., 2000</xref>; <xref rid="B17" ref-type="bibr">Dauber et al., 2006</xref>; <xref rid="B40" ref-type="bibr">Kochs et al., 2007</xref>; <xref rid="B30" ref-type="bibr">Hai et al., 2008</xref>; <xref rid="B31" ref-type="bibr">Hale et al., 2008a</xref>, <xref rid="B32" ref-type="bibr">b</xref>; <xref rid="B91" ref-type="bibr">Richt and Garcia-Sastre, 2009</xref>; <xref rid="B99" ref-type="bibr">Steel et al., 2009b</xref>; <xref rid="B100" ref-type="bibr">Steidle et al., 2010</xref>; <xref rid="B80" ref-type="bibr">Pachler and Vlasak, 2011</xref>; <xref rid="B85" ref-type="bibr">Pica et al., 2012</xref>; <xref rid="B16" ref-type="bibr">Dankar et al., 2013</xref>; <xref rid="B3" ref-type="bibr">Ayllon et al., 2014</xref>; <xref rid="B18" ref-type="bibr">DeDiego et al., 2016</xref>; <xref rid="B72" ref-type="bibr">Nogales et al., 2016b</xref>, <xref rid="B68" ref-type="bibr">2017b</xref>, <xref rid="B74" ref-type="bibr">2018a</xref>,<xref rid="B75" ref-type="bibr">b</xref>; <xref rid="B11" ref-type="bibr">Chauche et al., 2018</xref>; <xref rid="B94" ref-type="bibr">Rodriguez et al., 2018</xref>). NS1 is the primary transcript from the viral non-structural (NS) genome segment 8 (IAV and IBV) or 7 (ICV and IDV), which also encode the nuclear export protein (NEP) by using an alternative splicing mechanism (<xref rid="B43" ref-type="bibr">Lamb et al., 1980</xref>; <xref rid="B61" ref-type="bibr">Nakada et al., 1986</xref>; <xref rid="B60" ref-type="bibr">Muraki et al., 2010</xref>; <xref rid="B93" ref-type="bibr">Robb et al., 2010</xref>; <xref rid="B14" ref-type="bibr">Chua et al., 2013</xref>; <xref rid="B19" ref-type="bibr">Dela-Moss et al., 2014</xref>).</p><p>Studies describing the mechanisms of action of NS1 during viral infection have been primarily focused in IAV (<xref rid="B26" ref-type="bibr">Garcia-Sastre et al., 1998</xref>; <xref rid="B64" ref-type="bibr">Nemeroff et al., 1998</xref>; <xref rid="B20" ref-type="bibr">Falcon et al., 1999</xref>; <xref rid="B8" ref-type="bibr">Burgui et al., 2003</xref>; <xref rid="B107" ref-type="bibr">Twu et al., 2006</xref>; <xref rid="B29" ref-type="bibr">Guo et al., 2007</xref>; <xref rid="B40" ref-type="bibr">Kochs et al., 2007</xref>, <xref rid="B41" ref-type="bibr">2009</xref>; <xref rid="B54" ref-type="bibr">Mibayashi et al., 2007</xref>; <xref rid="B31" ref-type="bibr">Hale et al., 2008a</xref>, <xref rid="B32" ref-type="bibr">b</xref>, <xref rid="B33" ref-type="bibr">2010</xref>; <xref rid="B100" ref-type="bibr">Steidle et al., 2010</xref>; <xref rid="B16" ref-type="bibr">Dankar et al., 2013</xref>; <xref rid="B3" ref-type="bibr">Ayllon et al., 2014</xref>; <xref rid="B18" ref-type="bibr">DeDiego et al., 2016</xref>; <xref rid="B72" ref-type="bibr">Nogales et al., 2016b</xref>, <xref rid="B67" ref-type="bibr">2017a</xref>,<xref rid="B70" ref-type="bibr">d</xref>, <xref rid="B74" ref-type="bibr">2018a</xref>,<xref rid="B75" ref-type="bibr">b</xref>; <xref rid="B11" ref-type="bibr">Chauche et al., 2018</xref>; <xref rid="B94" ref-type="bibr">Rodriguez et al., 2018</xref>), IBV (<xref rid="B116" ref-type="bibr">Yuan and Krug, 2001</xref>; <xref rid="B17" ref-type="bibr">Dauber et al., 2006</xref>; <xref rid="B30" ref-type="bibr">Hai et al., 2008</xref>; <xref rid="B77" ref-type="bibr">Nogales et al., 2015</xref>; <xref rid="B83" ref-type="bibr">Patzina et al., 2017</xref>) and, to a less extent, ICV (<xref rid="B61" ref-type="bibr">Nakada et al., 1986</xref>; <xref rid="B60" ref-type="bibr">Muraki et al., 2010</xref>; <xref rid="B80" ref-type="bibr">Pachler and Vlasak, 2011</xref>). Nothing is currently known about the ability of IDV NS1 to counteract the IFN response. Moreover, it is unclear whether the NS1 proteins of IBV, ICV, or IDV have similar properties and/or mechanisms of anti-IFN activity than those of IAV NS1. Interestingly, the NS1 protein from an IAV-like virus of bat origin has been shown to also counteract the IFN system, but does not fully complement replication of IAV in mice when replacing the NS1 from a conventional IAV (<xref rid="B105" ref-type="bibr">Turkington et al., 2015</xref>, <xref rid="B106" ref-type="bibr">2018</xref>; <xref rid="B2" ref-type="bibr">Aydillo et al., 2018</xref>). In a recent study, a panel of recombinant viruses expressing different NS1 from human and avian origin were generated, showing that viruses encoding NS1 from human IAV induced higher levels of IFN in human dendritic cells than viruses expressing avian IAV NS1 proteins (<xref rid="B55" ref-type="bibr">Monteagudo et al., 2019</xref>). Therefore, there are several functional characteristics of influenza NS1 that remains elusive.</p><p>To evaluate the ability of IBV, ICV, and IDV NS1 proteins to functionally complement IAV NS1, we engineered recombinant influenza A/Puerto Rico/8/34 H1N1 (PR8) viruses expressing homotypic (IAV) or heterotypic (IBV, ICV, and IDV) NS1 proteins. To that end, we took advantage of our recently described NS split approach that allows the expression of NS1 independently of NEP from the same NS viral segment (<xref rid="B48" ref-type="bibr">Manicassamy et al., 2010</xref>; <xref rid="B71" ref-type="bibr">Nogales et al., 2016a</xref>, <xref rid="B72" ref-type="bibr">b</xref>, <xref rid="B70" ref-type="bibr">2017d</xref>, <xref rid="B74" ref-type="bibr">2018a</xref>). Our <italic>in vitro</italic> and <italic>in vivo</italic> characterization of the recombinant PR8 viruses suggested that despite the ability of IBV, ICV, and IDV NS1 proteins to effectively counteract IFN responses <italic>in vitro</italic>, viral fitness <italic>in vitro</italic> and virulence <italic>in vivo</italic> were compromised in PR8 viruses expressing heterotypic (IBV, ICV, and IDV) NS1 proteins. These results indicate that while IAV, IBV, ICV, and IDV NS1 proteins are capable of counteracting host IFN responses, other functions specific for IAV NS1 are not present in the heterotypic NS1 proteins, resulting in reduced replication and viral attenuation <italic>in vivo</italic>. Importantly, our findings also support the feasibility of using recombinant IAV expressing heterotypic (IBV, ICV, or IDV) NS1 proteins for the development of safe and effective live-attenuated influenza vaccines (LAIVs) for the prevention of IAV infections.</p></sec><sec id="S2"><title>Results</title><sec id="S2.SS1"><title>Ability of NS1 Proteins to Inhibit Host Gene Expression and Virus-Induced ISRE Promoter Activation</title><p>To evaluate the ability of NS1 proteins from different influenza viruses to inhibit general host protein expression or IFN-dependent responses, we selected representative members of each viral type (IAV, IBV, ICV, and IDV). Since the NS1 protein from some IAV strains have been shown to differ in inhibiting host gene expression (<xref rid="B64" ref-type="bibr">Nemeroff et al., 1998</xref>; <xref rid="B107" ref-type="bibr">Twu et al., 2006</xref>; <xref rid="B33" ref-type="bibr">Hale et al., 2010</xref>; <xref rid="B97" ref-type="bibr">Spesock et al., 2011</xref>; <xref rid="B16" ref-type="bibr">Dankar et al., 2013</xref>; <xref rid="B3" ref-type="bibr">Ayllon et al., 2014</xref>; <xref rid="B18" ref-type="bibr">DeDiego et al., 2016</xref>; <xref rid="B72" ref-type="bibr">Nogales et al., 2016b</xref>, <xref rid="B67" ref-type="bibr">2017a</xref>, <xref rid="B74" ref-type="bibr">2018a</xref>; <xref rid="B11" ref-type="bibr">Chauche et al., 2018</xref>), we selected A/Brevig Mission/1/18 H1N1 (1918) and A/Puerto Rico/8/34 H1N1 (PR8) as representative NS1 proteins with the ability to induce or not, respectively, cellular shutoff. Moreover, the antiviral functions of these two IAV NS1 proteins have been well-described in the literature (<xref rid="B100" ref-type="bibr">Steidle et al., 2010</xref>; <xref rid="B18" ref-type="bibr">DeDiego et al., 2016</xref>; <xref rid="B72" ref-type="bibr">Nogales et al., 2016b</xref>, <xref rid="B67" ref-type="bibr">2017a</xref>, <xref rid="B74" ref-type="bibr">2018a</xref>). To assess if the NS1 proteins from different origins were able to block polymerase II promoter-driven host gene expression (<xref ref-type="fig" rid="F1">Figure 1</xref>), human 293T cells were transiently co-transfected with individual plasmids encoding HA epitope tagged NS1 proteins from IAV (PR8 or 1918), IBV, ICV, or IDV; together with a plasmid expressing the Gaussia luciferase (Gluc) reporter gene (<xref ref-type="fig" rid="F1">Figure 1A</xref>). Cells transfected with an empty (E) plasmid were used as an internal control in these experiments. Gluc expression was evaluated using a luminometer (<xref ref-type="fig" rid="F1">Figure 1A</xref>) at 24 h post-transfection. As previously described (<xref rid="B100" ref-type="bibr">Steidle et al., 2010</xref>; <xref rid="B18" ref-type="bibr">DeDiego et al., 2016</xref>; <xref rid="B72" ref-type="bibr">Nogales et al., 2016b</xref>, <xref rid="B67" ref-type="bibr">2017a</xref>; <xref rid="B11" ref-type="bibr">Chauche et al., 2018</xref>; <xref rid="B94" ref-type="bibr">Rodriguez et al., 2018</xref>), PR8 NS1 did not inhibit Gluc reporter gene expression, whereas 1918 NS1 was able to efficiently inhibit protein expression of the reporter gene. IBV, ICV, and IDV NS1 proteins did not inhibit Gluc expression (<xref ref-type="fig" rid="F1">Figure 1A</xref>). Interestingly, a slight but statistical significant increase in the expression of Gluc was observed in cells transfected with plasmids encoding ICV and IDV NS1 proteins (<xref ref-type="fig" rid="F1">Figure 1A</xref>), although the biological significance for this observation needs to be evaluated. PR8 IAV, IBV, ICV, and IDV NS1 proteins were detected by Western blot using an antibody against the HA epitope tag (<xref ref-type="fig" rid="F1">Figure 1B</xref>), although different levels of expression were noted. We were not able to detect expression of 1918 NS1, mainly because of its ability to inhibit host gene expression, including its own synthesis (<xref ref-type="fig" rid="F1">Figure 1B</xref>), as previously described (<xref rid="B18" ref-type="bibr">DeDiego et al., 2016</xref>; <xref rid="B72" ref-type="bibr">Nogales et al., 2016b</xref>, <xref rid="B67" ref-type="bibr">2017a</xref>, <xref rid="B74" ref-type="bibr">2018a</xref>). These results demonstrate that the NS1 proteins from IBV, ICV, and IDV do not inhibit host gene expression, similar to PR8 IAV NS1.</p><fig id="F1" position="float"><label>FIGURE 1</label><caption><p>Ability of influenza NS1 proteins to inhibit host gene expression and ISRE promoter activation: Human 293T cells (2.5 &#x000d7; 10<sup>5</sup> cells/well, 24-well plate format, triplicates) were transiently co-transfected with 25 ng of polymerase II expression pCAGGS plasmids encoding Gluc together with 1 &#x003bc;g of the indicated HA epitope tagged IAV (PR8 and 1918), IBV, ICV, and IDV NS1 pCAGGS plasmids, or empty (E) pCAGGS plasmid as internal control. At 24 h post-transfection, Gluc activity in the tissue culture supernatants was evaluated using a Lumicount luminometer <bold>(A)</bold>. Results represent the means and standard deviation (SD) of triplicate values. <sup>&#x02217;</sup><italic>P</italic> &#x02264; 0.05 using Student&#x02019;s <italic>t</italic>-test (<italic>n</italic> = 3 per time point), for comparisons of cells transfected with E plasmid or plasmids encoding IAV (PR8 or 1918), IBV, ICV, or IDV NS1 proteins. <bold>(B)</bold> NS1 protein expression levels from transfected cells were evaluated by Western blot using an HA tag epitope antibody. Actin was used as loading control. Molecular mass markers (in kDa) are indicated on the left. <bold>(C,D)</bold> Ability of influenza NS1 proteins to inhibit ISRE promoter activation upon SeV infection: Human 293T cells (2.5 &#x000d7; 10<sup>5</sup> cells/well, 24-well plate format, triplicates) were transiently co-transfected, using the CaPO<sub>4</sub> method, with a reporter plasmid encoding FFluc under the control of an ISRE promoter (pISRE-FFluc), a plasmid constitutively expressing Rluc under the control of a polymerase II promoter (pSV40-Rluc), and the indicated HA epitope tagged IAV (PR8 and 1918), IBV, ICV, and IDV NS1 pCAGGS expressing plasmids, or empty (E) pCAGGS plasmid as control. At 20 h post-transfection, cells were mock infected (SeV&#x02013;) or infected (SeV +) with SeV (MOI = 3) to induce activation of the ISRE promoter, and, 24 h after SeV infection, cells were analyzed for FFluc and Rluc activities using a Lumicount luminometer (<bold>C</bold>). Results represent the means and SD of triplicate values. <sup>&#x02217;</sup><italic>P</italic> &#x02264; 0.05 or <sup>&#x02217;&#x02217;</sup><italic>P</italic> &#x02264; 0.001 using Student&#x02019;s <italic>t</italic>-test (<italic>n</italic> = 3 per time point), for comparisons of expression levels in SeV-infected cells previously transfected with E plasmid or plasmids encoding the NS1 from IAV (PR8 or 1918), IBV, ICV, or IDV. NS1 protein expression levels from total cell lysates were determined by Western blot as indicated above <bold>(D)</bold>. Experiments were repeated twice, with similar results.</p></caption><graphic xlink:href="fmicb-10-02862-g001"/></fig><p>We next evaluated the ability of the different NS1 proteins to counteract IFN responses. To that end, human 293T cells were transiently co-transfected with individual plasmids expressing the HA-tagged NS1 proteins of IAV (PR8 and 1918), IBV, ICV, or IDV; together with a plasmid expressing Firefly Luciferase (FFluc) under the control of an IFN-stimulated response element (ISRE) promoter and a plasmid constitutively expressing Renilla luciferase (Rluc) under a polymerase II dependent promoter (<xref ref-type="fig" rid="F1">Figure 1</xref>). Cells transfected with an empty (E) plasmid were used as a control. At 20 h post-transfection, cells were either mock infected (&#x02212;) or infected (+) with Sendai virus (SeV) for 24 h to induce ISRE promoter activation. FFluc expression was quantified and normalized to the levels of Rluc (<xref ref-type="fig" rid="F1">Figure 1C</xref>). While a strong activation of the ISRE promoter was observed after SeV infection in the empty plasmid control, SeV-infected cells transfected with IAV, IBV, ICV, or IDV NS1-expressing plasmids showed reduced ISRE promoter activation with values similar to those observed in mock-infected cells (<xref ref-type="fig" rid="F1">Figure 1C</xref>). Moreover, PR8 IAV, IBV, ICV, and IDV; but not 1918 IAV, NS1 proteins were detected by Western blot using an anti-HA epitope antibody (<xref ref-type="fig" rid="F1">Figure 1D</xref>). These results demonstrate that the NS1 proteins from IAV (PR8 and 1918), IBV, ICV, and IDV were all able to efficiently inhibit SeV-induced activation of the ISRE promoter.</p></sec><sec id="S2.SS2"><title>Generation and Characterization of Recombinant PR8 Viruses Expressing IAV, IBV, ICV, or IDV NS1 Proteins</title><p>Given that all tested NS1 proteins were able to inhibit virus-mediated ISRE promoter activation in transfected cells (<xref ref-type="fig" rid="F1">Figure 1</xref>), we next attempted to rescue recombinant PR8 viruses encoding homotypic IAV (PR8/ANS1) or heterotypic IBV (PR8/BNS1), ICV (PR8/CNS1), or IDV (PR8/DNS1) NS1 proteins (<xref ref-type="fig" rid="F2">Figure 2</xref>). To that end, the wild-type (WT) PR8 NS segment (<xref ref-type="fig" rid="F2">Figure 2A</xref>) was genetically modified to encode the viral NS1 and NEP open reading frames (ORFs) from the same viral transcript separated by the porcine teschovirus (PTV) 2A autoproteolytic cleavage site, as previously described (<xref rid="B48" ref-type="bibr">Manicassamy et al., 2010</xref>; <xref rid="B65" ref-type="bibr">Nogales et al., 2014a</xref>, <xref rid="B71" ref-type="bibr">2016a</xref>,<xref rid="B72" ref-type="bibr">b</xref>, <xref rid="B74" ref-type="bibr">2018a</xref>; <xref rid="B7" ref-type="bibr">Breen et al., 2016</xref>; <xref rid="B18" ref-type="bibr">DeDiego et al., 2016</xref>). Importantly, this construct allows us to express different NS1 sequences without affecting the amino acid sequence of NEP. We use the backbone of this new PR8 NS split segment to encode the different NS1 proteins with a C-terminal HA epitope tag (<xref ref-type="fig" rid="F2">Figure 2B</xref>).</p><fig id="F2" position="float"><label>FIGURE 2</label><caption><p>Generation and characterization of recombinant PR8 viruses expressing different NS1 proteins. <bold>(A)</bold> Schematic representation of PR8 WT NS segment: PR8 WT NS segment and gene products (NS1 and NEP) are indicated. <bold>(B)</bold> Schematic representation of PR8 viruses expressing different NS1 proteins: a modified PR8 NS segment encoding NS1 and NEP from the same transcript (top) and the PR8 viruses encoding the NS1 proteins from PR8 (PR8/ANS1), IBV (PR8/BNS1), ICV (PR8/CNS1), or IDV (PR8/DNS1) with an HA epitope tag at the C-terminal of NS1, or an PR8 NS1 deficient virus (PR8/&#x00394;NS1) are indicated. Black boxes at the beginning and end of each viral segment represent the viral 3&#x02032; and 5&#x02032; non-coding regions (NCR). Gray boxes indicate the viral NEP. White boxes show the different NS1 proteins. The PTV-1 2A autoproteolytic cleavage site used for the expression of NS1 and NEP from a single transcript is also indicated. <bold>(C)</bold> Immunofluorescence assay: MDCK cells (2.5 &#x000d7; 10<sup>5</sup> cells/well, 24-well plate format, triplicates) were mock-infected or infected (MOI = 2) with WT or modified PR8 viruses expressing IAV (PR8/ANS1), IBV (PR8/BNS1), ICV (PR8/CNS1) and IDV (PR8/DN1) NS1 proteins, or without NS1 (PR8/&#x00394;NS1). At 14 h post-infection, cells were fixed and stained for NS1 using HA epitope tag (top) or NP (bottom) antibodies (light blue). DAPI was used for nuclear staining (dark blue). Representative images were captured at 10x magnification. Scale bar: 100 &#x003bc;m. <bold>(D)</bold> Western blots: MDCK cells (2.5 &#x000d7; 10<sup>5</sup> cells/well, 24-well plate format) were mock-infected or infected as above and protein expression levels for NS1 and NP were evaluated using HA epitope tag or NP antibodies as described above. Actin was used as a loading control. Molecular mass markers (in kDa) are indicated on the left.</p></caption><graphic xlink:href="fmicb-10-02862-g002"/></fig><p>All the recombinant PR8/ANS1, PR8/BNS1, PR8/CNS1, and PR8/DNS1 viruses were successfully recovered, using plasmid-based reverse genetics techniques, and the identity of the rescued viruses was confirmed by immunofluorescence (<xref ref-type="fig" rid="F2">Figure 2C</xref>) and Western blot (<xref ref-type="fig" rid="F2">Figure 2D</xref>) analysis at 14 h post-infection (p.i.) in MDCK-infected [multiplicity of infection (MOI) = 2] cells, using specific antibodies against the HA epitope tag fused to NS1, and the viral NP protein. WT (PR8/WT) and NS1 deficient (PR8/&#x00394;NS1) PR8 viruses were included as internal controls. Only cells infected with the recombinant PR8 viruses encoding the HA-tagged NS1 proteins were detected with the HA epitope tag antibody by either immunofluorescence (<xref ref-type="fig" rid="F2">Figure 2C</xref>) or Western blot (<xref ref-type="fig" rid="F2">Figure 2D</xref>). On the other hand, NP expression was observed in all infected but not in mock-infected cells (<xref ref-type="fig" rid="F2">Figure 2D</xref>).</p><p>Next, we evaluated the replication properties of the recombinant PR8 viruses in cell culture by performing multicycle growth kinetics in canine MDCK (MOI = 0.001) (<xref ref-type="fig" rid="F3">Figure 3A</xref>) or human A549 (MOI = 0.01) (<xref ref-type="fig" rid="F3">Figure 3B</xref>) cells at 33&#x000b0;C. All recombinant PR8 viruses reached high titers in MDCK cells, although PR8/WT and PR8/ANS1 showed statistically significant higher viral titers than PR8/BNS1, PR8/CNS1, PR8/DNS1, and PR8/&#x00394;NS1 viruses at 24 and 48 h p.i. (<xref ref-type="fig" rid="F3">Figure 3A</xref>). These similarities, or differences, were more noticeably in A549 cells (<xref ref-type="fig" rid="F3">Figure 3B</xref>). PR8/WT and PR8/ANS1 reached similar viral titers in A549 cells while PR8/BNS1, PR8/CNS1, PR8/DNS1, and PR8/&#x00394;NS1 viruses grew at significant lower titers (10- to 1,000-fold decrease) than PR8/WT or PR8/ANS1 (<xref ref-type="fig" rid="F3">Figure 3B</xref>). Interestingly, while the replication of PR8/BNS1, PR8/CNS1, and PR8/DNS1 viruses increased in a time dependent matter, PR8/&#x00394;NS1 viral titers decreased over time (<xref ref-type="fig" rid="F3">Figure 3B</xref>), probably because PR8/&#x00394;NS1 lacks NS1 and, therefore, the ability to inhibit IFN (<xref rid="B26" ref-type="bibr">Garcia-Sastre et al., 1998</xref>). We also examined the phenotype of the different recombinant PR8 viruses in MDCK cells using plaque assays and immunostaining (<xref ref-type="fig" rid="F3">Figure 3C</xref>). As expected, based on our multicycle growth kinetics (<xref ref-type="fig" rid="F3">Figure 3A</xref>), PR8/WT and PR8/ANS1 have similar plaque sizes that were larger than those of the recombinant PR8 viruses encoding heterotypic NS1 proteins, and more noticeable, than the virus lacking NS1 (PR8/&#x00394;NS1) (<xref ref-type="fig" rid="F3">Figure 3C</xref>). Altogether, these data demonstrates that viral fitness of recombinant PR8 viruses expressing heterotypic IBV, ICV and IDV NS1 proteins, and more noticeable the virus without NS1, was impaired compared to PR8/WT or PR8/ANS1 in cultured cells, an effect that was more evident in A549 cells.</p><fig id="F3" position="float"><label>FIGURE 3</label><caption><p>Multicycle growth kinetics and plaque assay of recombinant WT and modified PR8 viruses. Viral growth kinetics: Canine MDCK <bold>(A)</bold> or human A549 <bold>(B)</bold> cells (2.5 &#x000d7; 10<sup>5</sup> cells/well, 24-well plate format, triplicates) were infected (MOI = 0.001 for MDCK; MOI = 0.01 for A549 cells) with the indicated WT or modified PR8 viruses and incubated at 33&#x000b0;C. Tissue culture supernatants were collected at the indicated hours post-infection and viral titers were determined by immunofocus assay (FFU/ml) using an anti-NP antibody (HB-65). Data represent the means and SD of the results determined from triplicate wells. Dashed lines indicate the limit of detection (200 FFU/ml). <sup>&#x02217;&#x02217;&#x02217;&#x02217;</sup>, <sup>&#x02217;&#x02217;&#x02217;</sup>, <sup>&#x02217;&#x02217;</sup>, <sup>&#x02217;</sup><italic>P</italic> &#x02264; 0.05 (PR8/ANS1 versus PR8/BNS1, PR8/ANS1 versus PR8/CNS1, PR8/ANS1 versus PR8/DNS1, and PR8/ANS1 versus PR8/&#x00394;NS1, respectively) using one-way ANOVA (<italic>n</italic> = 3 per time point). <bold>(C)</bold> Plaque assays: MDCK cells (10<sup>6</sup> cells/well, 6-well plate format) were infected with the indicated WT or modified PR8 viruses and incubated at 33&#x000b0;C for 3 days. Plaques were evaluated by immunostaining with the anti-NP antibody HB-65.</p></caption><graphic xlink:href="fmicb-10-02862-g003"/></fig></sec><sec id="S2.SS3"><title>Inhibition of IFN Induction by Recombinant PR8 Viruses <italic>in vitro</italic></title><p>Since the primary role of influenza NS1 protein is to inhibit IFN and host antiviral responses during viral infection (<xref rid="B32" ref-type="bibr">Hale et al., 2008b</xref>; <xref rid="B75" ref-type="bibr">Nogales et al., 2018b</xref>), we next explored the effect of expressing heterotypic NS1 proteins in the backbone of IAV PR8, on the ability of the virus to inhibit induction of IFN in infected cells using cell- and virus-based IFN bioassays (<xref ref-type="fig" rid="F4">Figure 4A</xref>). MDCK cells constitutively expressing FFluc reporter gene under the control of the IFN&#x003b2; promoter (MDCK IFN&#x003b2;-GFP/IFN&#x003b2;-FFluc) were mock-infected or infected (MOI = 3) with the recombinant PR8 viruses and, at 12 h p.i., we evaluated IFN&#x003b2; promoter activation by FFluc expression (<xref ref-type="fig" rid="F4">Figure 4B</xref>). As expected, FFluc activities were greater in cells infected with PR8/&#x00394;NS1 (<xref ref-type="fig" rid="F4">Figure 4B</xref>). However, FFluc expression levels were comparable between the PR8/WT and the homotypic (PR8/ANS1) or heterotypic (PR8/BNS1, PR8/CNS1, and PR8/DNS1) NS1-expressing recombinant viruses (<xref ref-type="fig" rid="F4">Figure 4B</xref>), indicating that they were able to similarly inhibit IFN&#x003b2; induction. Importantly, we observed similar levels of infection in MDCK cells with the different recombinant viruses (<xref ref-type="fig" rid="F4">Figure 4C</xref>). We also assessed the presence of IFN in tissue culture supernatants (TCSs) collected from the same virus-infected MDCK cells. To that end, fresh MDCK cells were treated with the UV-inactivated TCS from PR8 infected cells. At 24 h post-incubation, cells were infected (MOI = 3) with a recombinant Newcastle disease virus expressing GFP (rNDV-GFP), a virus previously described to be sensitive to the antiviral state induced by the present of IFN in TCS (<xref rid="B81" ref-type="bibr">Park et al., 2003</xref>). Then, 14 h p.i., GFP expression was evaluated using a fluorescent microplate reader (<xref ref-type="fig" rid="F4">Figure 4D</xref>). MDCK cells pre-treated with TCS from mock-infected cells were used as internal control. As expected, based on the levels of IFN&#x003b2; promoter activation (<xref ref-type="fig" rid="F4">Figure 4B</xref>), levels of rNDV-GFP replication were reduced in MDCK cells pre-treated with TCS of PR8 infected cells (<xref ref-type="fig" rid="F4">Figure 4D</xref>). Importantly, inhibition of rNDV-GFP was similar in MDCK cells treated with TCS from WT (PR8/WT), homotypic (PR8/ANS1) or heterotypic (PR8/BNS1, PR8/CNS1, and PR8/DNS1) infected cells. Moreover, inhibition of rNDV-GFP infection was more evident and significant in MDCK cells treated with TCS from PR8/&#x00394;NS1 infected cells (<xref ref-type="fig" rid="F4">Figure 4D</xref>). These results demonstrate that the NS1 protein from heterotypic IBV, ICV, and IDV have similar abilities to inhibit IFN responses as the homotypic IAV PR8 NS1 in infected MDCK cells.</p><fig id="F4" position="float"><label>FIGURE 4</label><caption><p>IFN&#x003b2; promoter activation and induction of an antiviral state by recombinant WT and modified PR8 viruses. <bold>(A)</bold> Schematic representation of the experimental approach. MDCK cells (2.5 &#x000d7; 10<sup>5</sup> cells/well, 24-well plate format, triplicates) expressing FFluc reporter gene under the control of the IFN&#x003b2; promoter (MDCK IFN&#x003b2;-GFP/-FFluc) were mock-infected or infected (MOI = 3) with the WT and modified PR8 viruses. At 12 h post-infection, IFN&#x003b2; promoter activation was determined by assessing FFluc expression level. <bold>(B)</bold> Viral infections were evaluated by immunofluorescence using the antibody against influenza NP. <bold>(C)</bold> Tissue culture supernatants from the same mock- or PR8-infected MDCK cells were collected and, after UV inactivation, used to treat fresh MDCK cells in 96-well plates (5 &#x000d7; 10<sup>4</sup> cells/well, 96-well plate format, triplicates) for 24 h prior to infection (MOI = 3) with rNDV-GFP. GFP expression from rNDV-GFP-infected cells was evaluated at 14 h post-infection using a fluorescent microplate reader <bold>(D)</bold>. <sup>&#x02217;</sup><italic>P</italic> &#x02264; 0.05 using Student&#x02019;s <italic>t</italic>-test (<italic>n</italic> = 3 per time point). Ns, not significant.</p></caption><graphic xlink:href="fmicb-10-02862-g004"/></fig></sec><sec id="S2.SS4"><title>Virulence of Recombinant PR8 Viruses in Mice</title><p>Given that we observed differences in the replication of recombinant PR8 viruses expressing different NS1 proteins in A549 cells (<xref ref-type="fig" rid="F3">Figure 3</xref>), we next evaluated and compared the virulence of the different recombinant PR8 viruses in a mouse model of influenza viral infection (<xref ref-type="fig" rid="F5">Figure 5</xref>). Groups of C57BL/6 WT mice (<italic>n</italic> = 5) were infected intranasally (i.n.) with 10<sup>3</sup>, 10<sup>4</sup>, 10<sup>5</sup>, or 10<sup>6</sup> plaque forming units (PFUs) of PR8/ANS1, PR8/BNS1, PR8/CNS1, PR8/DNS1, and PR8/&#x00394;NS1 and animals were monitored during 2 weeks for body weight loss (<xref ref-type="fig" rid="F5">Figure 5A</xref>) and mortality (<xref ref-type="fig" rid="F5">Figure 5B</xref>). Mice infected with PR8/ANS1 showed clear changes in mouse morbidity and mortality that were dose dependent (<xref ref-type="fig" rid="F5">Figures 5A,B</xref>, respectively). Importantly, and as previously described, approximately 50% of the mice infected with 10<sup>3</sup> PFU succumbed to PR8/ANS1 infection (<xref rid="B18" ref-type="bibr">DeDiego et al., 2016</xref>; <xref rid="B71" ref-type="bibr">Nogales et al., 2016a</xref>, <xref rid="B72" ref-type="bibr">b</xref>). As expected, PR8/&#x00394;NS1 was highly attenuated, with no changes in body weight and all the animals surviving viral infection, even with the highest dose of 10<sup>6</sup> PFU (<xref ref-type="fig" rid="F5">Figures 5A,B</xref>, respectively). Notably, PR8 viruses expressing heterotypic NS1 proteins (PR8/BNS1, PR8/CNS1, and PR8/DNS1) displayed similar levels of attenuation as PR8/&#x00394;NS1 (<xref ref-type="fig" rid="F5">Figures 5A,B</xref>), suggesting that the NS1 protein from IBV, ICV, and IDV cannot functionally substitute the NS1 protein of IAV.</p><fig id="F5" position="float"><label>FIGURE 5</label><caption><p>Virulence and replication of recombinant PR8 viruses in WT mice: groups of 5-to-6-week-old C57BL/6 female mice (<italic>n</italic> = 5) were infected intranasally with the indicated doses (10<sup>3</sup>, 10<sup>4</sup>, 10<sup>5</sup>, or 10<sup>6</sup> PFU) of PR8 viruses expressing IAV (PR8/ANS1), IBV (PR8/BNS1), ICV (PR8/CNS1) and IDV (PR8/DNS1) or with the NS1 deficient PR8 virus (PR8/&#x00394;NS1). Body weight loss <bold>(A)</bold> and survival <bold>(B)</bold> were evaluated daily for 2 weeks. Groups of mice (<italic>n</italic> = 3) were sacrificed at days 2 and 4 post-infection and lungs were harvested, homogenized and used to quantify viral titers <bold>(C)</bold> by immunofocus assay (FFU/ml). Symbols represent data from individual mice. Bars represent the means of lung viral titers. &#x00026; Infectious virus was detected only in 1 of 3 mice. Black dotted lines indicates the limit of detection (100 FFU/ml). <sup>&#x02217;</sup><italic>P</italic> &#x02264; 0.05 using Student&#x02019;s <italic>t</italic>-test.</p></caption><graphic xlink:href="fmicb-10-02862-g005"/></fig><p>To assess whether the observed attenuation correlated with virus replication in the lungs of infected mice, groups of C57BL/6 WT mice (<italic>n</italic> = 6) were infected i.n. with the same viral doses (10<sup>3</sup>, 10<sup>4</sup>, 10<sup>5</sup>, or 10<sup>6</sup> PFU) of PR8/ANS1, PR8/BNS1, PR8/CNS1, PR8/DNS1, and PR8/&#x00394;NS1 viruses; and viral titers were evaluated at days 2 (<italic>n</italic> = 3) and 4 (<italic>n</italic> = 3) p.i. (<xref ref-type="fig" rid="F5">Figure 5C</xref>). Similar to the morbidity and mortality data, animals infected with PR8/ANS1 virus showed high levels of viral replication [&#x0003e;10<sup>6</sup> fluorescent forming units (FFU/ml)] at both days 2 and 4 p.i. for all different doses (<xref ref-type="fig" rid="F5">Figure 5C</xref>). Remarkably, virus replication was limited in PR8/BNS1, PR8/CNS1 and PR8/DNS1 infected mice, to levels comparable to PR8/&#x00394;NS1 infected animals (<xref ref-type="fig" rid="F5">Figure 5C</xref>). No virus was recovered in any of the mice infected at lower MOI (10<sup>3</sup> and 10<sup>4</sup> PFU), and low virus titers were detected in mice infected with 10<sup>5</sup> PFU of PR8/BNS1 and PR8/DNS1. Different viral titers were recovered from the lungs of mice infected with the highest dose (10<sup>6</sup> PFU) of PR8/BNS1, PR8/CNS1, PR8/DNS1, and PR8/&#x00394;NS1 (<xref ref-type="fig" rid="F5">Figure 5C</xref>). In all the cases, virus loads with all the four viruses (PR8/BNS1, PR8/CNS1, PR8/DNS1, and PR8/&#x00394;NS1) were at least three to four orders of magnitude lower than those observed with PR8/ANS1 (<xref ref-type="fig" rid="F5">Figure 5C</xref>). Importantly, virus titers in the lungs correlated with the low morbidity and mortality observed in infected mice (<xref ref-type="fig" rid="F5">Figures 5A,B</xref>, respectively) and with viral replication in cultured cells (<xref ref-type="fig" rid="F3">Figures 3A,B</xref>).</p><p>In order to assess the induction of host innate immune responses after infection (<xref ref-type="fig" rid="F6">Figure 6</xref>), groups of C57BL/6 WT mice (<italic>n</italic> = 12) were infected i.n. with 10<sup>5</sup> (<italic>n</italic> = 6) or 10<sup>6</sup> (<italic>n</italic> = 6) PFU of PR8/ANS1, PR8/BNS1, PR8/CNS1, PR8/DNS1, and PR8/&#x00394;NS1; sacrificed at days 2 (<italic>n</italic> = 3) and 4 (<italic>n</italic> = 3) p.i. and IFN&#x003b2; (<xref ref-type="fig" rid="F6">Figure 6A</xref>), chemokine CC motif ligand 2 (CCL2) (<xref ref-type="fig" rid="F6">Figure 6B</xref>), and IFN-induced protein with tetratricopeptide repeats 2 (IFIT2) (<xref ref-type="fig" rid="F6">Figure 6C</xref>) mRNA expression levels were measured in the lungs by reverse transcription-quantitative PCR (RT-qPCR). PR8/ANS1 infection induced the strongest cytokine responses <italic>in vivo</italic> at both days p.i. with either 10<sup>5</sup> or 10<sup>6</sup> PFU, which most likely reflects the ability of the virus to efficiently replicate in the lungs of infected mice (<xref ref-type="fig" rid="F6">Figure 6</xref>). In contrast, mice infected with PR8/BNS1, PR8/CNS1, PR8/DNS1, or PR8/&#x00394;NS1 showed reduced levels for IFN&#x003b2; (<xref ref-type="fig" rid="F6">Figure 6A</xref>), CCL2 (<xref ref-type="fig" rid="F6">Figure 6B</xref>), and IFIT2 (<xref ref-type="fig" rid="F6">Figure 6C</xref>) mRNA expression, which also correlated with low viral replication observed in the lungs of infected mice (<xref ref-type="fig" rid="F5">Figure 5</xref>).</p><fig id="F6" position="float"><label>FIGURE 6</label><caption><p>Induction of innate immune responses by recombinant PR8 viruses in WT mice: mRNA expression levels of IFN&#x003b2; <bold>(A)</bold>, CCL2 <bold>(B)</bold>, and IFIT2 <bold>(C)</bold> in lungs of 5-to-6-week-old C57BL/6 female mice infected with 10<sup>5</sup> (left) or 10<sup>6</sup> (right) PFU of the indicated PR8 viruses at days 2 and 4 post-infection (<italic>n</italic> = 3) were quantified by RT-qPCR. Fold expression changes in each mouse group were calculated relative to the mock (PBS) control group. Data represent the averages and SD values for three mice in each group on the indicated days post-infection. <sup>&#x02217;</sup><italic>P</italic> &#x02264; 0.05 or <sup>&#x02217;&#x02217;</sup><italic>P</italic> &#x02264; 0.001 using two-way ANOVA.</p></caption><graphic xlink:href="fmicb-10-02862-g006"/></fig><p>Signal transducer and activator of transcription 2 (STAT2) is critical for type I and type III IFN signaling and plays an important role in host defense responses against viral infections (<xref rid="B56" ref-type="bibr">Morrison and Garcia-Sastre, 2014</xref>; <xref rid="B28" ref-type="bibr">Grant et al., 2016</xref>; <xref rid="B108" ref-type="bibr">Uccellini and Garcia-Sastre, 2018</xref>). Phosphorylation of STAT2 (and STAT1) leads to their dimerization and translocation to the cell nucleus where they act as transcription factors for the activation of multiple ISGs, which limit viral replication and induce an antiviral state in the same or neighbor cells (<xref rid="B6" ref-type="bibr">Blaszczyk et al., 2016</xref>). Given that type I and type III IFN signaling relies on STAT2 activation, absence of STAT2 allows a more targeted assessment of type I and type III IFN-mediated immune responses. Moreover, it has been previously shown that influenza-infected STAT2<sup>&#x02013;/&#x02013;</sup> B6 mice have increased morbidity and mortality when compared to WT B6 mice (<xref rid="B27" ref-type="bibr">Gopal et al., 2018</xref>). Therefore, we evaluated the virulence of PR8/BNS1, PR8/CNS1 and PR8/DNS1 in C57BL/6 STAT2<sup>&#x02013;/&#x02013;</sup> mice and compared them to that of the parental PR8/WT and PR8/ANS1 viruses (<xref ref-type="fig" rid="F7">Figure 7</xref>). To that end, male C57BL/6 STAT2<sup>&#x02013;/&#x02013;</sup> mice (<italic>n</italic> = 3) were infected i.n. with 10<sup>6</sup> PFU of PR8/WT, PR8/ANS1, PR8/BNS1, PR8/CNS1, and PR8/DNS1 or mock-infected and changes in body weight (<xref ref-type="fig" rid="F7">Figure 7A</xref>) and survival (<xref ref-type="fig" rid="F7">Figure 7B</xref>) were monitored daily for 14 days. All mice infected with PR8/WT or PR8/ANS1 rapidly lost weight and succumbed to viral infection by day 5 after infection. Although PR8/BNS1, PR8/CNS1, and PR8/DNS1 viruses were still attenuated as compared to PR8/WT or PR8/ANS1, the recombinant PR8 viruses expressing heterosubtypic NS1 proteins were able to induce morbidity and mortality in the STAT2<sup>&#x02013;/&#x02013;</sup> infected mice (<xref ref-type="fig" rid="F7">Figures 7A,B</xref>, respectively). To further characterize <italic>in vivo</italic> virulence, female STAT2<sup>&#x02013;/&#x02013;</sup> mice were infected with 10<sup>6</sup> PFU of the same recombinant viruses and viral lung replication was analyzed at days 2 and 4 p.i. (<italic>n</italic> = 3 for the heterotypic viruses and <italic>n</italic> = 2 for PR8/WT at each time point) (<xref ref-type="fig" rid="F7">Figure 7C</xref>). In agreement with the pathogenicity data, lower viral titers were detected in the lungs of STAT2<sup>&#x02013;/&#x02013;</sup> mice infected with PR8/BNS1, PR8/CNS1, or PR8/DNS1 as compared to mice infected with PR8/WT or PR8/ANS1 (<xref ref-type="fig" rid="F7">Figure 7C</xref>). Altogether, these data demonstrate that although recombinant PR8 viruses expressing IBV, ICV, and IDV NS1 proteins are able to counteract IFN responses in cultured cells, these heterotypic NS1 proteins cannot entirely complement the functions of IAV NS1 <italic>in vivo</italic> resulting in reduced viral fitness and replication and, therefore, virulence.</p><fig id="F7" position="float"><label>FIGURE 7</label><caption><p>Characterization of recombinant PR8 viruses in STAT2<sup>&#x02013;/&#x02013;</sup> mice: groups of six-to-8-week-old C57BL/6 STAT2<sup>&#x02013;/&#x02013;</sup> mice were infected intranasally with 10<sup>6</sup> PFU of the indicated recombinant PR8 viruses, or PBS as internal control. Mean body weight loss <bold>(A)</bold> and survival <bold>(B)</bold> are shown. Error bars represent SDs. <bold>(C)</bold> Viral titers in the lungs of animals infected with 10<sup>6</sup> PFU at days 2 and 4 post-infection. Symbols represent data from individual mice. Bars represent the means of lung viral titers. The black dotted lines indicates the limit of detection (100 FFU/ml). <sup>&#x02217;</sup><italic>P</italic> &#x02264; 0.05 using Student&#x02019;s <italic>t</italic>-test.</p></caption><graphic xlink:href="fmicb-10-02862-g007"/></fig></sec></sec><sec id="S3"><title>Discussion</title><p>Defense strategies provided by the innate immune system limit virus replication (<xref rid="B89" ref-type="bibr">Randall and Goodbourn, 2008</xref>; <xref rid="B10" ref-type="bibr">Carrero, 2013</xref>). However, viruses encode proteins that counteract the antiviral mechanisms of the host cell (<xref rid="B109" ref-type="bibr">Wang et al., 2007</xref>; <xref rid="B38" ref-type="bibr">Iwasaki and Pillai, 2014</xref>; <xref rid="B75" ref-type="bibr">Nogales et al., 2018b</xref>). Influenza NS1 protein is highly expressed in infected cells and prevents the activation of key players in the IFN system, allowing the virus to replicate and spread, representing an important viral pathogenesis factor (<xref rid="B26" ref-type="bibr">Garcia-Sastre et al., 1998</xref>; <xref rid="B32" ref-type="bibr">Hale et al., 2008b</xref>; <xref rid="B49" ref-type="bibr">Marc, 2014</xref>; <xref rid="B18" ref-type="bibr">DeDiego et al., 2016</xref>; <xref rid="B72" ref-type="bibr">Nogales et al., 2016b</xref>, <xref rid="B74" ref-type="bibr">2018a</xref>,<xref rid="B75" ref-type="bibr">b</xref>). Currently, there are four types of influenza viruses: IAV, IBV, ICV and the newly identified IDV (<xref rid="B114" ref-type="bibr">Wright et al., 2007</xref>; <xref rid="B12" ref-type="bibr">Chen and Holmes, 2008</xref>; <xref rid="B112" ref-type="bibr">Wanitchang et al., 2012</xref>; <xref rid="B104" ref-type="bibr">Tong et al., 2013</xref>; <xref rid="B4" ref-type="bibr">Baker et al., 2014</xref>; <xref rid="B115" ref-type="bibr">Yoon et al., 2014</xref>; <xref rid="B36" ref-type="bibr">Hengrung et al., 2015</xref>; <xref rid="B53" ref-type="bibr">Matsuzaki et al., 2016</xref>; <xref rid="B110" ref-type="bibr">Wang et al., 2016</xref>; <xref rid="B24" ref-type="bibr">Foni et al., 2017</xref>; <xref rid="B69" ref-type="bibr">Nogales et al., 2017c</xref>; <xref rid="B101" ref-type="bibr">Su et al., 2017</xref>; <xref rid="B62" ref-type="bibr">Nakatsu et al., 2018</xref>; <xref rid="B1" ref-type="bibr">Asha and Kumar, 2019</xref>; <xref rid="B117" ref-type="bibr">Zhang et al., 2019</xref>). Despite the divergence of their genomes and host range, all types of influenza viruses express NS1 proteins. The NS1 protein of IAV has been extensively studied and multiple functions, including counteraction of cellular antiviral responses, have been previously described (<xref rid="B35" ref-type="bibr">Hatada et al., 1992</xref>, <xref rid="B34" ref-type="bibr">1997</xref>; <xref rid="B20" ref-type="bibr">Falcon et al., 1999</xref>; <xref rid="B44" ref-type="bibr">Li et al., 2006</xref>; <xref rid="B29" ref-type="bibr">Guo et al., 2007</xref>; <xref rid="B40" ref-type="bibr">Kochs et al., 2007</xref>; <xref rid="B78" ref-type="bibr">Opitz et al., 2007</xref>; <xref rid="B32" ref-type="bibr">Hale et al., 2008b</xref>). Likewise, IBV NS1 has been previously shown to inhibit host innate responses, mainly IFN (<xref rid="B116" ref-type="bibr">Yuan and Krug, 2001</xref>; <xref rid="B17" ref-type="bibr">Dauber et al., 2006</xref>; <xref rid="B30" ref-type="bibr">Hai et al., 2008</xref>; <xref rid="B83" ref-type="bibr">Patzina et al., 2017</xref>). Although less studied, ICV NS1 has also been shown to inhibit IFN responses (<xref rid="B61" ref-type="bibr">Nakada et al., 1986</xref>; <xref rid="B60" ref-type="bibr">Muraki et al., 2010</xref>; <xref rid="B80" ref-type="bibr">Pachler and Vlasak, 2011</xref>). To date, the ability of IDV NS1 to counteract innate immune responses have not been described. Despite their similarities in inhibiting IFN, the amino acid sequence of IAV, IBV, ICV, and IDV NS1 proteins are very different, suggesting that the mechanism(s) of counteracting host innate immune responses and/or interactions with host proteins involved in the IFN pathway, could be different for the NS1 proteins of these diverse influenza viruses. The IBV, ICV, and IDV NS1 proteins tested in our study do not have the ability to inhibit host gene expression (<xref ref-type="fig" rid="F1">Figure 1</xref>), similar to some IAV strains, such as PR8 (<xref rid="B40" ref-type="bibr">Kochs et al., 2007</xref>). However, all of them were able to inhibit ISRE promoter activation induced by SeV infection (<xref ref-type="fig" rid="F1">Figure 1</xref>). This is, to our knowledge, the first time that IDV NS1 has been shown to inhibit induction of IFN responses, similar to the NS1 proteins from IAV, IBV, and ICV. Based on their ability to inhibit IFN responses, one could postulate that the NS1 protein of an influenza virus could be exchanged for that of other virus types. In this study we aimed to determine if the NS1 proteins from IBV, ICV, or IDV can functionally replace the NS1 of IAV. To address this hypothesis, we generated recombinant PR8 viruses expressing homotypic (PR8) or heterotypic (IBV, ICV, and IDV) NS1 proteins. To that end, we took advantage of our newly described IAV PR8 modified NS segment that allows the expression of NS1 independently of NEP (<xref rid="B7" ref-type="bibr">Breen et al., 2016</xref>; <xref rid="B18" ref-type="bibr">DeDiego et al., 2016</xref>; <xref rid="B71" ref-type="bibr">Nogales et al., 2016a</xref>, <xref rid="B72" ref-type="bibr">b</xref>, <xref rid="B70" ref-type="bibr">2017d</xref>, <xref rid="B74" ref-type="bibr">2018a</xref>) (<xref ref-type="fig" rid="F2">Figure 2</xref>). Our studies suggest that although the replication of IAV expressing heterotypic IBV, ICV, and IDV NS1 proteins was not severely impaired in MDCK cells (<xref ref-type="fig" rid="F3">Figure 3</xref>) and the viruses were able to inhibit IFN response to levels comparable to PR8/WT (<xref ref-type="fig" rid="F4">Figure 4</xref>), viral replication was impaired in human A549 cells (<xref ref-type="fig" rid="F3">Figure 3</xref>). In addition, our results <italic>in vivo</italic> showed that virulence and replication of IAV expressing heterotypic NS1 proteins were also affected in WT mice (<xref ref-type="fig" rid="F5">Figure 5</xref>). Notably, the virulence and replication of PR8 viruses expressing heterotypic NS1 proteins were still maintained, although to a minor extent, in STAT2<sup>&#x02013;/&#x02013;</sup> mice (<xref ref-type="fig" rid="F7">Figure 7</xref>), suggesting that although IBV, ICV, and IDV NS1 proteins are able to counteract IFN responses similar to IAV NS1 <italic>in vitro</italic>, they cannot complement additional functions that are required for viral replication and virulence.</p><p>IAV NS1, through its N-terminal domain, is able to bind multiple RNA molecules (<xref rid="B49" ref-type="bibr">Marc, 2014</xref>), including polyadenylated mRNAs, double stranded (ds)RNAs, small nuclear RNAs, viral genomic RNAs or messenger (m)RNAs (<xref rid="B35" ref-type="bibr">Hatada et al., 1992</xref>, <xref rid="B34" ref-type="bibr">1997</xref>; <xref rid="B47" ref-type="bibr">Lu et al., 1994</xref>; <xref rid="B87" ref-type="bibr">Qiu and Krug, 1994</xref>; <xref rid="B88" ref-type="bibr">Qiu et al., 1995</xref>; <xref rid="B50" ref-type="bibr">Marion et al., 1997</xref>; <xref rid="B111" ref-type="bibr">Wang and Krug, 1998</xref>; <xref rid="B103" ref-type="bibr">Terrier et al., 2013</xref>). In addition, more than 50 host proteins have been described to interact with IAV NS1 (<xref rid="B49" ref-type="bibr">Marc, 2014</xref>; <xref rid="B75" ref-type="bibr">Nogales et al., 2018b</xref>), although there is some variability among the NS1 binding partners between different IAV strains, most likely due to host-adaptation mechanisms (<xref rid="B67" ref-type="bibr">Nogales et al., 2017a</xref>, <xref rid="B74" ref-type="bibr">2018a</xref>,<xref rid="B75" ref-type="bibr">b</xref>; <xref rid="B11" ref-type="bibr">Chauche et al., 2018</xref>; <xref rid="B94" ref-type="bibr">Rodriguez et al., 2018</xref>). Furthermore, IAV NS1 is also able to interact with viral proteins such as the polymerase acid (PA) or NP (<xref rid="B92" ref-type="bibr">Robb et al., 2011</xref>; <xref rid="B49" ref-type="bibr">Marc, 2014</xref>). Through these numerous interactions, IAV NS1 is able to inhibit antiviral responses and translation, regulate the activity of the viral polymerase complex and, therefore, synthesis of vRNA; and control several processes related with the cellular or vRNA metabolism (RNA splicing, mRNA nuclear export, etc.). Currently, knowledge on the ability of IBV, ICV, and IDV NS1 proteins to bind RNA or cellular proteins is more limited, and these differences could explain the attenuation of PR8 viruses expressing heterotypic NS1 proteins.</p><p>Moreover, our results have also an important translational application. Since recombinant IAV expressing heterotypic (IBV, ICV, or IDV) NS1 proteins are highly attenuated, with limited replication <italic>in vivo</italic> as compared to viruses expressing the homotypic IAV NS1 protein, these viruses could be used as safe, immunogenic and protective LAIVs for the prevention of viral infections. Compared to the previously described approaches, including the use of a NS1 deficient virus, LAIVs based on IAV expressing heterotypic NS1 proteins present the following advantages: (1) IAV expressing heterotypic NS1 proteins replicate more efficiently in culture cells than NS1 deficient viruses, representing an advantage for vaccine production; (2) IAV expressing heterotypic NS1 proteins would ensure that the viruses are attenuated <italic>in vivo</italic> but they conserve their ability to counteract, to some extent, the IFN response; and (3) therefore, they could induce innate immune responses that can act as a natural adjuvant to control viral replication and to enhance host adaptive immune response to provide better protection (<xref rid="B23" ref-type="bibr">Fernandez-Sesma et al., 2006</xref>; <xref rid="B22" ref-type="bibr">Fernandez-Sesma, 2007</xref>; <xref rid="B58" ref-type="bibr">Mueller et al., 2010</xref>).</p><p>Altogether, our data suggest that despite the similarities to effectively counteract IFN responses, the NS1 proteins of IBV, ICV, or IDV do not fully complement the activities of the multifunctional IAV NS1 protein. Our results also open the feasibility of conducting similar studies in the backbone of other influenza types (e.g., IBV, ICV, and IDV) to evaluate the contribution of their NS1 proteins in viral pathogenesis and in the feasibility of complementing them with the NS1 protein from heterotypic viruses.</p></sec><sec sec-type="materials|methods" id="S4"><title>Materials and Methods</title><sec id="S4.SS1"><title>Cell Lines and Viruses</title><p>Human embryonic kidney 293T (American Type Culture Collection, ATCC, CRL-11268), human lung epithelial carcinoma A549 (ATCC CCL-185) and Madin-Darby canine kidney (MDCK, ATCC CCL-34) cells were grown in Dulbecco&#x02019;s modified Eagle&#x02019;s medium (DMEM; Mediatech, Inc.) supplemented with 5% fetal bovine serum (FBS; Atlanta Biologicals) and 1% penicillin (100 units/ml)&#x02013;streptomycin (100 &#x003bc;g/ml)&#x02013;2 mM <sc>L</sc>-glutamine (P-S-G; Mediatech, Inc.) at 37&#x000b0;C in air enriched with 5% CO<sub>2</sub>. MDCK cells constitutively expressing the green fluorescent protein (GFP) and firefly luciferase (FFluc) reporter genes under the control of the IFN&#x003b2; promoter (MDCK IFN&#x003b2;-GFP/IFN&#x003b2;-FFluc) were previously described (<xref rid="B30" ref-type="bibr">Hai et al., 2008</xref>). Influenza A/Puerto Rico/8/1934 (PR8) H1N1 wild-type (WT) and &#x00394;NS1 viruses, Cantell strain of Sendai virus (SeV), and the recombinant Newcastle disease virus (rNDV) expressing GFP (rNDV-GFP) were also previously described (<xref rid="B26" ref-type="bibr">Garcia-Sastre et al., 1998</xref>; <xref rid="B81" ref-type="bibr">Park et al., 2003</xref>; <xref rid="B52" ref-type="bibr">Martinez-Sobrido et al., 2006</xref>; <xref rid="B40" ref-type="bibr">Kochs et al., 2007</xref>; <xref rid="B15" ref-type="bibr">Cox et al., 2015</xref>; <xref rid="B71" ref-type="bibr">Nogales et al., 2016a</xref>).</p></sec><sec id="S4.SS2"><title>Plasmids</title><p>Polymerase II expression plasmids containing the NS1 sequences from influenza B/Brisbane/60/2008 (IBV), C/Taylor/1233/1947 (ICV), or D/Swine/Oklahoma/1334/2011 (IDV) fused to an HA epitope tag (YPYDVPDYA) were generated using standard molecular biology techniques. Briefly, the different NS1 ORFs were amplified by RT-PCR using oligonucleotides with the appropriate flanking restriction sites (<italic>Sac</italic>I and <italic>Sma</italic>I) for cloning into pCAGGS-HA-COOH (<xref rid="B54" ref-type="bibr">Mibayashi et al., 2007</xref>) using <italic>Sac</italic>I and <italic>Sma</italic>I restriction sites. The pCAGGS plasmids encoding the NS1 genes of IAV PR8 and A/Brevig Mission/01/1918 H1N1 (1918) have been previously described (<xref rid="B40" ref-type="bibr">Kochs et al., 2007</xref>; <xref rid="B54" ref-type="bibr">Mibayashi et al., 2007</xref>).</p><p>In order to generate ambisense pDZ-NS plasmids containing the different IAV (PR8), IBV, ICV, and IDV NS1 proteins and the same IAV PR8 NEP, we used our previously described pDZ-NS-2xBsmBI plasmid (<xref rid="B65" ref-type="bibr">Nogales et al., 2014a</xref>), which contains the PR8 NS1, without the stop codon or splice acceptor site, and two <italic>Bsm</italic>BI sites, followed by the porcine teschovirus-1 (PTV-1) 2A autoproteolytic cleavage site (ATNFSLLKQAGDVEENPGP) and the PR8 NEP. The PR8 NS1 was removed from the pDZ-NS-2xBsmBI plasmid by inverse PCR to generate pDZ-&#x00394;NS1-2xBsmBI. Next, the different IBV, ICV, or IDV ORFs were amplified by PCR from the pCAGGs-NS1 plasmids with primers containing <italic>Bsm</italic>BI sites and an HA tag at the C-terminal. NS1 PCR products were cloned into the pDZ-&#x00394;NS1-2xBsmBI plasmid using the <italic>Bsm</italic>BI restriction sites. All the plasmid constructs were confirmed by sequencing (ACGT, Inc.). Sequences of the primers used for the construction of the different plasmids are available upon request.</p></sec><sec id="S4.SS3"><title>Rescue of Recombinant PR8 Viruses</title><p>Ambisense pDZ plasmids were used for the rescue of the recombinant PR8 viruses as previously described (<xref rid="B66" ref-type="bibr">Nogales et al., 2014b</xref>, <xref rid="B71" ref-type="bibr">2016a</xref>; <xref rid="B7" ref-type="bibr">Breen et al., 2016</xref>; <xref rid="B73" ref-type="bibr">Nogales and Martinez-Sobrido, 2016</xref>). Briefly, co-cultures (1:1) of 293T/MDCK cells (6-well plate format, 10<sup>6</sup> cells/well) were co-transfected in suspension, using Lipofectamine 2000 (LPF2000, Invitrogen), with the PR8 ambisense pDZ-PB2, -PB1, -PA, -HA, -NP, -NA, -M plasmids and the NS plasmids containing IAV (PR8), IBV (B/Brisbane/60/2008), ICV (C/Taylor/1233/1947) or IDV (D/Swine/Oklahoma/1334/2011) NS1 proteins. Clonal viruses were selected by plaque assay, and virus stocks were propagated in MDCK cells at 33&#x000b0;C in a 5% CO<sub>2</sub> atmosphere for 3&#x02013;4 days. For infections, virus stocks were diluted in phosphate buffered saline (PBS) supplemented with 0.3% bovine albumin (BA) and 1% PS (PBS/BA/PS). After viral infections, cells were maintained in DMEM supplemented with 0.3% BA, 1% PSG, and 1 &#x003bc;g/ml tosyl-sulfonyl phenylalanyl chloromethyl ketone (TPCK)-treated trypsin (Sigma). Virus titers were determined by standard plaque assay (plaque forming units [PFU]/ml) in MDCK cells (<xref rid="B66" ref-type="bibr">Nogales et al., 2014b</xref>, <xref rid="B71" ref-type="bibr">2016a</xref>; <xref rid="B7" ref-type="bibr">Breen et al., 2016</xref>; <xref rid="B73" ref-type="bibr">Nogales and Martinez-Sobrido, 2016</xref>).</p></sec><sec id="S4.SS4"><title>Inhibition of Host Gene Expression</title><p>To evaluate the effects of the different viral NS1 proteins on host protein synthesis, human 293T cells (24-well plate format, 2.5 &#x000d7; 10<sup>5</sup> cells/well, triplicates) were transiently co-transfected, using LPF2000, with 1 &#x003bc;g/well of the indicated pCAGGS-HA COOH NS1 expression plasmids or an empty plasmid as control, together with 25 ng/well of pCAGGS plasmid expressing Gaussia luciferase (Gluc) (<xref rid="B9" ref-type="bibr">Capul and de la Torre, 2008</xref>). At 24 h post-transfection, Gluc activity was quantified from tissue culture supernatants using a Biolux Gaussia luciferase reagent (New England Bio-Labs) and a Lumicount luminometer (PacKard). The mean values and standard deviations (SD) were calculated using Microsoft Excel software.</p></sec><sec id="S4.SS5"><title>Inhibition of ISRE Promoter Activation</title><p>To evaluate the ability of the different NS1 proteins to inhibit activation of an IFN-stimulated response element (ISRE) promoter upon SeV infection, human 293T cells (24-well plate format, 2.5 &#x000d7; 10<sup>5</sup> cells/well, triplicates) were co-transfected with 1 &#x003bc;g of the different pCAGGS-HA NS1-expressing plasmids or empty plasmid as a control, together with 0.25 &#x003bc;g/well of a plasmid expressing FFluc under the control of an ISRE promoter (pISRE-FFluc) (<xref rid="B40" ref-type="bibr">Kochs et al., 2007</xref>; <xref rid="B67" ref-type="bibr">Nogales et al., 2017a</xref>; <xref rid="B94" ref-type="bibr">Rodriguez et al., 2018</xref>), and a plasmid constitutively expressing Renilla luciferase under a constitutively expressing simian virus 40 promoter (pSV40-Rluc) using a calcium phosphate-based mammalian transfection kit (Stratagene). At 20 h post-transfection, cells were infected (MOI = 3) with SeV, Cantell strain (<xref rid="B40" ref-type="bibr">Kochs et al., 2007</xref>; <xref rid="B67" ref-type="bibr">Nogales et al., 2017a</xref>; <xref rid="B94" ref-type="bibr">Rodriguez et al., 2018</xref>), to induce activation of the ISRE promoter, and 24 h post-infection, FFluc and Rluc activities were quantified from cell lysates using luciferase reporter buffers (Promega) and a Lumicount luminometer (PacKard). FFluc/Rluc activation was shown as fold-induction compared to mock-infected cells in the absence of NS1 protein (empty plasmid). The mean values and SD were calculated using Microsoft Excel software.</p></sec><sec id="S4.SS6"><title>SDS-PAGE and Western Blot Analysis</title><p>Total proteins from transfected or infected cell lysates were separated by denaturing electrophoresis in 10% SDS-polyacrylamide gels and transferred to nitrocellulose membranes (Bio-Rad). Membranes were blocked for 1 h with 5% dried skim milk in PBS containing 0.1% Tween 20 (PBS-Tween) and incubated overnight at 4&#x000b0;C with rabbit polyclonal anti-HA (Sigma; to detect expression of NS1) or mouse monoclonal anti-NP (HB-65; ATCC H16-L10-4R5) antibodies. An anti-&#x003b2;-actin monoclonal antibody (Sigma) was used as a loading control. Horseradish peroxidase (HRP) secondary antibodies (GE Healthcare) specific for mouse or rabbit immunoglobulins (Ig) were used to detect bound primary antibodies. Proteins were detected by chemiluminescence using the Super Signal West Femto maximum-sensitivity substrate (Thermo Scientific) following the manufacturer&#x02019;s instructions.</p></sec><sec id="S4.SS7"><title>Immunofluorescence Assays</title><p>MDCK cells were mock infected or infected (MOI = 3) with the indicated PR8 viruses. At 14 h post-infection, cells were fixed with 4% paraformaldehyde (PFA) and permeabilized with 0.5% Triton X-100 in PBS for 15 min at room temperature. Immunostaining was performed as described previously (<xref rid="B66" ref-type="bibr">Nogales et al., 2014b</xref>, <xref rid="B71" ref-type="bibr">2016a</xref>; <xref rid="B7" ref-type="bibr">Breen et al., 2016</xref>; <xref rid="B73" ref-type="bibr">Nogales and Martinez-Sobrido, 2016</xref>), using primary rabbit polyclonal anti-HA (Sigma; to detect NS1 expression) or mouse monoclonal anti-NP (HB-65) antibodies and FITC-conjugated anti-mouse or anti-rabbit secondary antibodies (Dako). Cell nuclei were stained with 4&#x02032;,6&#x02032;-diamidino-2-phenylindole (DAPI, Research Organics). Images were taken with a fluorescence microscope (Nikon Eclipse TE2000).</p></sec><sec id="S4.SS8"><title>Virus Growth Kinetics</title><p>To assess virus multicycle growth rates, confluent monolayers MDCK or A549 cells (12-well plate format, 5 &#x000d7; 10<sup>5</sup> cells/well, triplicates) were infected at a MOI of 0.001 or 0.01, respectively. After 1 h of virus adsorption at room temperature, cells were incubated in DMEM supplemented with 0.3% BSA, PSG, and TPCK-treated trypsin at 33&#x000b0;C. At the indicated times post-infection (24, 48, 72, and 96 h), tissue culture supernatants were collected and titrated on MDCK cells in 96-well plates by an immunofluorescence assay (fluorescent forming units [FFU/ml]) using an influenza virus anti-NP antibody (HB-65) as previously described (<xref rid="B65" ref-type="bibr">Nogales et al., 2014a</xref>, <xref rid="B66" ref-type="bibr">b</xref>). The mean values and SD were calculated using Microsoft Excel software.</p></sec><sec id="S4.SS9"><title>Plaque Assays</title><p>Confluent monolayers of MDCK cells (6-well plate format, 10<sup>6</sup> cells/well) were infected with the indicated PR8 viruses for 1 h at room temperature, and after virus adsorption, cells were overlaid with media containing agar and incubated at 33&#x000b0;C. At 3 days post-infection, cells were fixed with 4% paraformaldehyde for 1 h at room temperature. Then, the overlays were removed, cells were permeabilized (0.5% Triton X-100 in PBS) for 15 min at room temperature, and immunostained, as previously described (<xref rid="B67" ref-type="bibr">Nogales et al., 2017a</xref>, <xref rid="B70" ref-type="bibr">d</xref>), using the anti-NP antibody HB-65 and vector kits (Vectastain ABC kit and DAB HRP substrate kit; Vector) according to the manufacturer&#x02019;s specifications.</p></sec><sec id="S4.SS10"><title><italic>In vivo</italic> Experiments</title><p>Studies with C57BL/6 WT or STAT2<sup>&#x02013;/&#x02013;</sup> were conducted at the University of Rochester or Icahn School of Medicine at Mount Sinai, respectively.</p><p>All protocols involving C57BL/6 WT mice have been approved by the University of Rochester Committee of Animal Resources and complied with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Research Council (<xref rid="B63" ref-type="bibr">National Research Council (U.S.) Committee for the Update of the Guide for the Care and Use of Laboratory Animals et al., 2011</xref>). C57BL/6 WT were purchased from the National Cancer Institute (NCI) and maintained in the animal care facility at University of Rochester under specific pathogen-free conditions. Six-to-8-week-old C57BL/6 WT mice were anesthetized intraperitoneally (i.p.) with 2,2,2-tribromoethanol (Avertin; 240 mg/kg of body weight) and infected intranasally (i.n.) with the indicated viruses. Mice (<italic>n</italic> = 5) were examined daily for morbidity (body weight loss) and mortality (survival). Mice showing a &#x0003e; 25% loss of their initial body weight were considered to have reached the experimental endpoint and were humanely euthanized. Virus replication was assessed by evaluating viral titers in the lungs of infected mice at days 2 and 4 post-infection. To that end, C57BL/6 WT mice (<italic>n</italic> = 3/day) were euthanized by administration of a lethal dose of Avertin and bleeding, and lungs were surgically extracted and homogenized in 1 ml of PBS/BA/PS (<xref rid="B95" ref-type="bibr">Rodriguez et al., 2017</xref>). Virus titers were determined by immunofocus assay (fluorescent forming units [FFU/ml]) in MDCK cells as previously described (<xref rid="B65" ref-type="bibr">Nogales et al., 2014a</xref>, <xref rid="B66" ref-type="bibr">b</xref>, <xref rid="B77" ref-type="bibr">2015</xref>, <xref rid="B71" ref-type="bibr">2016a</xref>; <xref rid="B15" ref-type="bibr">Cox et al., 2015</xref>; <xref rid="B7" ref-type="bibr">Breen et al., 2016</xref>).</p><p>Levels of IFN&#x003b2;, chemokine (C&#x02013;C) motif ligand 2 (CCL2), and IFN-induced protein with tetratricopeptide repeats 2 (IFIT2) induction were analyzed in mouse lungs at 2 and 4 days post-infection. To that end, mice (<italic>n</italic> = 3) were sacrificed as above, and their lungs were extracted and incubated in RNAlater (Ambion) at 4&#x000b0;C for 24 h prior to freezing at &#x02212;80&#x000b0;C. Lungs were homogenized in lysis buffer by use of a gentleMACS dissociator (Miltenyi Biotec), and total RNA was extracted with an RNeasy minikit (Qiagen) according to the manufacturer&#x02019;s recommendations. Reverse transcriptase reactions were conducted at 37&#x000b0;C for 2 h using a High-Capacity cDNA reverse transcription kit (Applied Biosystems) and a dT primer to amplify mRNAs. Quantitative PCRs (qPCRs) were performed using TaqMan gene expression assays (Applied Biosystems) specific for the murine genes IFN&#x003b2; (Mm00439552_s1), IFIT2 (Mm00492606_m1), and CCL2 (Mm00441242_m1). The 2<sup>&#x02013;&#x00394;</sup>
<sup>&#x00394;</sup>
<sup>CT</sup> method was used for quantification, and values were presented as fold induction in infected mice compared to non-infected mice (<xref rid="B45" ref-type="bibr">Livak and Schmittgen, 2001</xref>).</p><p>STAT2<sup>&#x02013;/&#x02013;</sup> C57BL/6 mice were originally provided by Dr. Christian Schindler. The latter STAT2<sup>&#x02013;/&#x02013;</sup> mice were then bred locally. Mice were housed in a barrier facility at the Icahn School of Medicine at Mount Sinai under specific pathogen free conditions. All mouse procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of the Icahn School of Medicine at Mount Sinai and performed in accordance with the IACUC guidelines. Six-to-8-week-old C57BL/6 STAT2<sup>&#x02013;/&#x02013;</sup> mice were anesthetized by inhalation of 4% isoflurane and inoculated i.n. at the indicated amount of viruses. Mice (<italic>n</italic> = 5 for WT or <italic>n</italic> = 3 for STAT2<sup>&#x02013;/&#x02013;</sup>) were examined daily for morbidity (body weight loss) and mortality as indicated above. To evaluate viral replication, C57BL/6 STAT2<sup>&#x02013;/&#x02013;</sup> mice (<italic>n</italic> = 3 for ABCD NS1-expressing recombinant viruses, <italic>n</italic> = 2 for PR8/WT virus) were euthanized by inhalation of 2% CO<sub>2</sub> followed by cervical dislocation. The lungs were excised on day 2 or day 4 post-infection, and viral titers were determined by plaque assay in MDCK cells. Mice were distributed by sex because of limited availability. Male mice were used to evaluate morbidity and female mice were used to assess viral replication.</p></sec></sec><sec sec-type="data-availability" id="S5"><title>Data Availability Statement</title><p>All datasets generated for this study are included in the article/supplementary material.</p></sec><sec id="S6"><title>Ethics Statement</title><p>The animal study was reviewed and approved by Studies with C57BL/6 WT or STAT2&#x02013;/&#x02013; were conducted at the University of Rochester or Icahn School of Medicine at Mount Sinai, respectively. All protocols involving C57BL/6 WT mice have been approved by the University of Rochester Committee of Animal Resources and complied with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Research Council (<xref rid="B63" ref-type="bibr">National Research Council (U.S.) Committee for the Update of the Guide for the Care and Use of Laboratory Animals et al., 2011</xref>). All mouse procedures were approved by Institutional Animal Care and Use Committee (IACUC) of the Icahn School of Medicine at Mount Sinai and performed in accordance with the IACUC guidelines.</p></sec><sec id="S7"><title>Author Contributions</title><p>LM-S, AN, and AG-S conceived the experiments. AN, TA, G&#x000c1;-P, AE, KC, RC, and MD conducted the experiments. AN and LM-S wrote the manuscript. FL provided critical reagents. All authors critically reviewed the manuscript.</p></sec><sec id="conf1"><title>Conflict of Interest</title><p>AG-S is a named co-inventor on technology patents own by Icahn School of Medicine at Mount Sinai (ISMMS) related to using live attenuated influenza virus vaccines lacking the NS1 virulence gene, exclusively licensed to Vivaldi Biosciences, Inc. AG-S is a co-founder of and holds equity in Vivaldi Biosciences, Inc., a privately-held start-up company in which ISMMS also holds equity. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> This research was partially funded by the New York Influenza Center of Excellence (NYICE), a member of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services, Centers of Excellence for Influenza Research and Surveillance (CEIRS) Contract No. HHSN272201400005C (NYICE); by the Department of Defense (DoD) Peer Reviewed Medical Research Program (PRMRP) grant W81XWH-18-1-0460 to LM-S; by the NIH R01AI141889 to FL; and by the Center for Research in Influenza Pathogenesis (CRIP, CEIRS Contract No. HHSN272201400008C to AG-S).</p></fn></fn-group><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asha</surname><given-names>K.</given-names></name><name><surname>Kumar</surname><given-names>B.</given-names></name></person-group> (<year>2019</year>). <article-title>Emerging influenza D virus threat: what we know so far!</article-title>
<source><italic>J. Clin. Med.</italic></source>
<volume>8</volume>:<issue>E192</issue>. <pub-id pub-id-type="doi">10.3390/jcm8020192</pub-id>
<?supplied-pmid 30764577?><pub-id pub-id-type="pmid">30764577</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aydillo</surname><given-names>T.</given-names></name><name><surname>Ayllon</surname><given-names>J.</given-names></name><name><surname>Pavlisin</surname><given-names>A.</given-names></name><name><surname>Martinez-Romero</surname><given-names>C.</given-names></name><name><surname>Tripathi</surname><given-names>S.</given-names></name><name><surname>Mena</surname><given-names>I.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Specific mutations in the PB2 protein of influenza A virus compensate for the lack of efficient interferon antagonism of the NS1 protein of bat influenza A-like viruses.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>92</volume>:<issue>e002021-17</issue>. <pub-id pub-id-type="doi">10.1128/JVI.02021-17JVI.02021-17</pub-id>
<?supplied-pmid 29321309?><pub-id pub-id-type="pmid">29321309</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayllon</surname><given-names>J.</given-names></name><name><surname>Domingues</surname><given-names>P.</given-names></name><name><surname>Rajsbaum</surname><given-names>R.</given-names></name><name><surname>Miorin</surname><given-names>L.</given-names></name><name><surname>Schmolke</surname><given-names>M.</given-names></name><name><surname>Hale</surname><given-names>B. G.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>A single amino acid substitution in the novel H7N9 influenza A virus NS1 protein increases F30 binding and virulence.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>88</volume>
<fpage>12146</fpage>&#x02013;<lpage>12151</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01567-14</pub-id>
<?supplied-pmid 25078692?><pub-id pub-id-type="pmid">25078692</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>S. F.</given-names></name><name><surname>Nogales</surname><given-names>A.</given-names></name><name><surname>Finch</surname><given-names>C.</given-names></name><name><surname>Tuffy</surname><given-names>K. M.</given-names></name><name><surname>Domm</surname><given-names>W.</given-names></name><name><surname>Perez</surname><given-names>D. R.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Influenza A and B virus intertypic reassortment through compatible viral packaging signals.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>88</volume>
<fpage>10778</fpage>&#x02013;<lpage>10791</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01440-14</pub-id>
<?supplied-pmid 25008914?><pub-id pub-id-type="pmid">25008914</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanco-Lobo</surname><given-names>P.</given-names></name><name><surname>Nogales</surname><given-names>A.</given-names></name><name><surname>Rodriguez</surname><given-names>L.</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name></person-group> (<year>2019</year>). <article-title>Novel approaches for the development of live attenuated influenza vaccines.</article-title>
<source><italic>Viruses</italic></source>
<volume>11</volume>:<issue>E190</issue>. <pub-id pub-id-type="doi">10.3390/v11020190</pub-id>
<?supplied-pmid 30813325?><pub-id pub-id-type="pmid">30813325</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blaszczyk</surname><given-names>K.</given-names></name><name><surname>Nowicka</surname><given-names>H.</given-names></name><name><surname>Kostyrko</surname><given-names>K.</given-names></name><name><surname>Antonczyk</surname><given-names>A.</given-names></name><name><surname>Wesoly</surname><given-names>J.</given-names></name><name><surname>Bluyssen</surname><given-names>H. A.</given-names></name></person-group> (<year>2016</year>). <article-title>The unique role of STAT2 in constitutive and IFN-induced transcription and antiviral responses.</article-title>
<source><italic>Cytokine Growth Factor Rev.</italic></source>
<volume>29</volume>
<fpage>71</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/j.cytogfr.2016.02.010</pub-id>
<?supplied-pmid 27053489?><pub-id pub-id-type="pmid">27053489</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breen</surname><given-names>M.</given-names></name><name><surname>Nogales</surname><given-names>A.</given-names></name><name><surname>Baker</surname><given-names>S. F.</given-names></name><name><surname>Perez</surname><given-names>D. R.</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name></person-group> (<year>2016</year>). <article-title>Replication-competent influenza A and B viruses expressing a fluorescent dynamic timer protein for in vitro and in vivo studies.</article-title>
<source><italic>PLoS One</italic></source>
<volume>11</volume>:<issue>e0147723</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0147723</pub-id>
<?supplied-pmid 26809059?><pub-id pub-id-type="pmid">26809059</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgui</surname><given-names>I.</given-names></name><name><surname>Aragon</surname><given-names>T.</given-names></name><name><surname>Ortin</surname><given-names>J.</given-names></name><name><surname>Nieto</surname><given-names>A.</given-names></name></person-group> (<year>2003</year>). <article-title>PABP1 and eIF4GI associate with influenza virus NS1 protein in viral mRNA translation initiation complexes.</article-title>
<source><italic>J. Gen. Virol.</italic></source>
<volume>84</volume>(<issue>Pt 12</issue>), <fpage>3263</fpage>&#x02013;<lpage>3274</lpage>. <pub-id pub-id-type="doi">10.1099/vir.0.19487-0</pub-id>
<?supplied-pmid 14645908?><pub-id pub-id-type="pmid">14645908</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capul</surname><given-names>A. A.</given-names></name><name><surname>de la Torre</surname><given-names>J. C.</given-names></name></person-group> (<year>2008</year>). <article-title>A cell-based luciferase assay amenable to high-throughput screening of inhibitors of arenavirus budding.</article-title>
<source><italic>Virology</italic></source>
<volume>382</volume>
<fpage>107</fpage>&#x02013;<lpage>114</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2008.09.008</pub-id>
<?supplied-pmid 18929379?><pub-id pub-id-type="pmid">18929379</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrero</surname><given-names>J. A.</given-names></name></person-group> (<year>2013</year>). <article-title>Confounding roles for type I interferons during bacterial and viral pathogenesis.</article-title>
<source><italic>Int. Immunol.</italic></source>
<volume>25</volume>
<fpage>663</fpage>&#x02013;<lpage>669</lpage>. <pub-id pub-id-type="doi">10.1093/intimm/dxt050</pub-id>
<?supplied-pmid 24158954?><pub-id pub-id-type="pmid">24158954</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chauche</surname><given-names>C.</given-names></name><name><surname>Nogales</surname><given-names>A.</given-names></name><name><surname>Zhu</surname><given-names>H.</given-names></name><name><surname>Goldfarb</surname><given-names>D.</given-names></name><name><surname>Ahmad Shanizza</surname><given-names>A. I.</given-names></name><name><surname>Gu</surname><given-names>Q.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Mammalian adaptation of an avian influenza A virus involves stepwise changes in NS1.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>92</volume>:<issue>e01875-17</issue>. <pub-id pub-id-type="doi">10.1128/JVI.01875-17</pub-id>
<?supplied-pmid 29237841?><pub-id pub-id-type="pmid">29237841</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>R.</given-names></name><name><surname>Holmes</surname><given-names>E. C.</given-names></name></person-group> (<year>2008</year>). <article-title>The evolutionary dynamics of human influenza B virus.</article-title>
<source><italic>J. Mol. Evol.</italic></source>
<volume>66</volume>
<fpage>655</fpage>&#x02013;<lpage>663</lpage>. <pub-id pub-id-type="doi">10.1007/s00239-008-9119-z</pub-id>
<?supplied-pmid 18504518?><pub-id pub-id-type="pmid">18504518</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>A. C.</given-names></name><name><surname>Subbarao</surname><given-names>K.</given-names></name></person-group> (<year>2018</year>). <article-title>Epidemiological data on the effectiveness of influenza vaccine-another piece of the puzzle.</article-title>
<source><italic>J. Infect Dis.</italic></source>
<volume>218</volume>
<fpage>176</fpage>&#x02013;<lpage>178</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jix635</pub-id>
<?supplied-pmid 29361111?><pub-id pub-id-type="pmid">29361111</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chua</surname><given-names>M. A.</given-names></name><name><surname>Schmid</surname><given-names>S.</given-names></name><name><surname>Perez</surname><given-names>J. T.</given-names></name><name><surname>Langlois</surname><given-names>R. A.</given-names></name><name><surname>Tenoever</surname><given-names>B. R.</given-names></name></person-group> (<year>2013</year>). <article-title>Influenza A virus utilizes suboptimal splicing to coordinate the timing of infection.</article-title>
<source><italic>Cell Rep.</italic></source>
<volume>3</volume>
<fpage>23</fpage>&#x02013;<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2012.12.010</pub-id>
<?supplied-pmid 23333274?><pub-id pub-id-type="pmid">23333274</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>A.</given-names></name><name><surname>Baker</surname><given-names>S. F.</given-names></name><name><surname>Nogales</surname><given-names>A.</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name><name><surname>Dewhurst</surname><given-names>S.</given-names></name></person-group> (<year>2015</year>). <article-title>Development of a mouse-adapted live attenuated influenza virus that permits in vivo analysis of enhancements to the safety of live attenuated influenza virus vaccine.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>89</volume>
<fpage>3421</fpage>&#x02013;<lpage>3426</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02636-14</pub-id>
<?supplied-pmid 25552727?><pub-id pub-id-type="pmid">25552727</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dankar</surname><given-names>S. K.</given-names></name><name><surname>Miranda</surname><given-names>E.</given-names></name><name><surname>Forbes</surname><given-names>N. E.</given-names></name><name><surname>Pelchat</surname><given-names>M.</given-names></name><name><surname>Tavassoli</surname><given-names>A.</given-names></name><name><surname>Selman</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Influenza A/Hong Kong/156/1997(H5N1) virus NS1 gene mutations F103L and M106I both increase IFN antagonism, virulence and cytoplasmic localization but differ in binding to RIG-I and CPSF30.</article-title>
<source><italic>Virol. J.</italic></source>
<volume>10</volume>:<issue>243</issue>. <pub-id pub-id-type="doi">10.1186/1743-422X-10-243</pub-id>
<?supplied-pmid 23886034?><pub-id pub-id-type="pmid">23886034</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dauber</surname><given-names>B.</given-names></name><name><surname>Schneider</surname><given-names>J.</given-names></name><name><surname>Wolff</surname><given-names>T.</given-names></name></person-group> (<year>2006</year>). <article-title>Double-stranded RNA binding of influenza B virus nonstructural NS1 protein inhibits protein kinase R but is not essential to antagonize production of alpha/beta interferon.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>80</volume>
<fpage>11667</fpage>&#x02013;<lpage>11677</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01142-06</pub-id>
<?supplied-pmid 16987984?><pub-id pub-id-type="pmid">16987984</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeDiego</surname><given-names>M. L.</given-names></name><name><surname>Nogales</surname><given-names>A.</given-names></name><name><surname>Lambert-Emo</surname><given-names>K.</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name><name><surname>Topham</surname><given-names>D. J.</given-names></name></person-group> (<year>2016</year>). <article-title>NS1 protein mutation I64T affects interferon responses and virulence of circulating H3N2 human influenza A viruses.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>90</volume>
<fpage>9693</fpage>&#x02013;<lpage>9711</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01039-16</pub-id>
<?supplied-pmid 27535054?><pub-id pub-id-type="pmid">27535054</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dela-Moss</surname><given-names>L. I.</given-names></name><name><surname>Moss</surname><given-names>W. N.</given-names></name><name><surname>Turner</surname><given-names>D. H.</given-names></name></person-group> (<year>2014</year>). <article-title>Identification of conserved RNA secondary structures at influenza B and C splice sites reveals similarities and differences between influenza A, B, and C.</article-title>
<source><italic>BMC Res. Notes</italic></source>
<volume>7</volume>:<issue>22</issue>. <pub-id pub-id-type="doi">10.1186/1756-0500-7-22</pub-id>
<?supplied-pmid 24405943?><pub-id pub-id-type="pmid">24405943</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falcon</surname><given-names>A. M.</given-names></name><name><surname>Fortes</surname><given-names>P.</given-names></name><name><surname>Marion</surname><given-names>R. M.</given-names></name><name><surname>Beloso</surname><given-names>A.</given-names></name><name><surname>Ortin</surname><given-names>J.</given-names></name></person-group> (<year>1999</year>). <article-title>Interaction of influenza virus NS1 protein and the human homologue of Staufen in vivo and in vitro.</article-title>
<source><italic>Nucleic Acids Res.</italic></source>
<volume>27</volume>
<fpage>2241</fpage>&#x02013;<lpage>2247</lpage>. <pub-id pub-id-type="doi">10.1093/nar/27.11.2241</pub-id>
<?supplied-pmid 10325410?><pub-id pub-id-type="pmid">10325410</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Federici</surname><given-names>C.</given-names></name><name><surname>Cavazza</surname><given-names>M.</given-names></name><name><surname>Costa</surname><given-names>F.</given-names></name><name><surname>Jommi</surname><given-names>C.</given-names></name></person-group> (<year>2018</year>). <article-title>Health care costs of influenza-related episodes in high income countries: a systematic review.</article-title>
<source><italic>PLoS One</italic></source>
<volume>13</volume>:<issue>e0202787</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0202787</pub-id>
<?supplied-pmid 30192781?><pub-id pub-id-type="pmid">30192781</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-Sesma</surname><given-names>A.</given-names></name></person-group> (<year>2007</year>). <article-title>The influenza virus NS1 protein: inhibitor of innate and adaptive immunity.</article-title>
<source><italic>Infect. Disord. Drug Targets</italic></source>
<volume>7</volume>
<fpage>336</fpage>&#x02013;<lpage>343</lpage>. <pub-id pub-id-type="doi">10.2174/187152607783018754</pub-id>
<?supplied-pmid 18220965?><pub-id pub-id-type="pmid">18220965</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-Sesma</surname><given-names>A.</given-names></name><name><surname>Marukian</surname><given-names>S.</given-names></name><name><surname>Ebersole</surname><given-names>B. J.</given-names></name><name><surname>Kaminski</surname><given-names>D.</given-names></name><name><surname>Park</surname><given-names>M. S.</given-names></name><name><surname>Yuen</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Influenza virus evades innate and adaptive immunity via the NS1 protein.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>80</volume>
<fpage>6295</fpage>&#x02013;<lpage>6304</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02381-05</pub-id>
<?supplied-pmid 16775317?><pub-id pub-id-type="pmid">16775317</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foni</surname><given-names>E.</given-names></name><name><surname>Chiapponi</surname><given-names>C.</given-names></name><name><surname>Baioni</surname><given-names>L.</given-names></name><name><surname>Zanni</surname><given-names>I.</given-names></name><name><surname>Merenda</surname><given-names>M.</given-names></name><name><surname>Rosignoli</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Influenza D in Italy: towards a better understanding of an emerging viral infection in swine.</article-title>
<source><italic>Sci. Rep.</italic></source>
<volume>7</volume>:<issue>11660</issue>. <pub-id pub-id-type="doi">10.1038/s41598-017-12012-3</pub-id>
<?supplied-pmid 28916759?><pub-id pub-id-type="pmid">28916759</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fouchier</surname><given-names>R. A.</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A.</given-names></name><name><surname>Kawaoka</surname><given-names>Y.</given-names></name><name><surname>Barclay</surname><given-names>W. S.</given-names></name><name><surname>Bouvier</surname><given-names>N. M.</given-names></name><name><surname>Brown</surname><given-names>I. H.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Transmission studies resume for avian flu.</article-title>
<source><italic>Science</italic></source>
<volume>339</volume>
<fpage>520</fpage>&#x02013;<lpage>521</lpage>. <pub-id pub-id-type="doi">10.1126/science.1235140</pub-id>
<?supplied-pmid 23345603?><pub-id pub-id-type="pmid">23345603</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Sastre</surname><given-names>A.</given-names></name><name><surname>Egorov</surname><given-names>A.</given-names></name><name><surname>Matassov</surname><given-names>D.</given-names></name><name><surname>Brandt</surname><given-names>S.</given-names></name><name><surname>Levy</surname><given-names>D. E.</given-names></name><name><surname>Durbin</surname><given-names>J. E.</given-names></name><etal/></person-group> (<year>1998</year>). <article-title>Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems.</article-title>
<source><italic>Virology</italic></source>
<volume>252</volume>
<fpage>324</fpage>&#x02013;<lpage>330</lpage>. <pub-id pub-id-type="doi">10.1006/viro.1998.9508</pub-id>
<?supplied-pmid 9878611?><pub-id pub-id-type="pmid">9878611</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gopal</surname><given-names>R.</given-names></name><name><surname>Lee</surname><given-names>B.</given-names></name><name><surname>McHugh</surname><given-names>K. J.</given-names></name><name><surname>Rich</surname><given-names>H. E.</given-names></name><name><surname>Ramanan</surname><given-names>K.</given-names></name><name><surname>Mandalapu</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>STAT2 signaling regulates macrophage phenotype during influenza and bacterial super-infection.</article-title>
<source><italic>Front. Immunol.</italic></source>
<volume>9</volume>:<issue>2151</issue>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.02151</pub-id>
<?supplied-pmid 30337919?><pub-id pub-id-type="pmid">30337919</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grant</surname><given-names>A.</given-names></name><name><surname>Ponia</surname><given-names>S. S.</given-names></name><name><surname>Tripathi</surname><given-names>S.</given-names></name><name><surname>Balasubramaniam</surname><given-names>V.</given-names></name><name><surname>Miorin</surname><given-names>L.</given-names></name><name><surname>Sourisseau</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Zika virus targets human STAT2 to inhibit type I interferon signaling.</article-title>
<source><italic>Cell Host Microbe</italic></source>
<volume>19</volume>
<fpage>882</fpage>&#x02013;<lpage>890</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2016.05.009</pub-id>
<?supplied-pmid 27212660?><pub-id pub-id-type="pmid">27212660</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>L. M.</given-names></name><name><surname>Zeng</surname><given-names>H.</given-names></name><name><surname>Gomez</surname><given-names>J. A.</given-names></name><name><surname>Plowden</surname><given-names>J.</given-names></name><name><surname>Fujita</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>NS1 protein of influenza A virus inhibits the function of intracytoplasmic pathogen sensor, RIG-I.</article-title>
<source><italic>Am. J. Respir. Cell Mol. Biol.</italic></source>
<volume>36</volume>
<fpage>263</fpage>&#x02013;<lpage>269</lpage>. <pub-id pub-id-type="doi">10.1165/rcmb.2006-0283RC</pub-id>
<?supplied-pmid 17053203?><pub-id pub-id-type="pmid">17053203</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hai</surname><given-names>R.</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name><name><surname>Fraser</surname><given-names>K. A.</given-names></name><name><surname>Ayllon</surname><given-names>J.</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A.</given-names></name><name><surname>Palese</surname><given-names>P.</given-names></name></person-group> (<year>2008</year>). <article-title>Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>82</volume>
<fpage>10580</fpage>&#x02013;<lpage>10590</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01213-08</pub-id>
<?supplied-pmid 18768976?><pub-id pub-id-type="pmid">18768976</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hale</surname><given-names>B. G.</given-names></name><name><surname>Barclay</surname><given-names>W. S.</given-names></name><name><surname>Randall</surname><given-names>R. E.</given-names></name><name><surname>Russell</surname><given-names>R. J.</given-names></name></person-group> (<year>2008a</year>). <article-title>Structure of an avian influenza A virus NS1 protein effector domain.</article-title>
<source><italic>Virology</italic></source>
<volume>378</volume>
<fpage>1</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2008.05.026</pub-id>
<?supplied-pmid 18585749?><pub-id pub-id-type="pmid">18585749</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hale</surname><given-names>B. G.</given-names></name><name><surname>Randall</surname><given-names>R. E.</given-names></name><name><surname>Ortin</surname><given-names>J.</given-names></name><name><surname>Jackson</surname><given-names>D.</given-names></name></person-group> (<year>2008b</year>). <article-title>The multifunctional NS1 protein of influenza A viruses.</article-title>
<source><italic>J. Gen. Virol.</italic></source>
<volume>89</volume>(<issue>Pt 10</issue>), <fpage>2359</fpage>&#x02013;<lpage>2376</lpage>. <pub-id pub-id-type="doi">10.1099/vir.0.2008/004606-0</pub-id>
<?supplied-pmid 18796704?><pub-id pub-id-type="pmid">18796704</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hale</surname><given-names>B. G.</given-names></name><name><surname>Steel</surname><given-names>J.</given-names></name><name><surname>Medina</surname><given-names>R. A.</given-names></name><name><surname>Manicassamy</surname><given-names>B.</given-names></name><name><surname>Ye</surname><given-names>J.</given-names></name><name><surname>Hickman</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Inefficient control of host gene expression by the 2009 pandemic H1N1 influenza A virus NS1 protein.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>84</volume>
<fpage>6909</fpage>&#x02013;<lpage>6922</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00081-10</pub-id>
<?supplied-pmid 20444891?><pub-id pub-id-type="pmid">20444891</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatada</surname><given-names>E.</given-names></name><name><surname>Saito</surname><given-names>S.</given-names></name><name><surname>Okishio</surname><given-names>N.</given-names></name><name><surname>Fukuda</surname><given-names>R.</given-names></name></person-group> (<year>1997</year>). <article-title>Binding of the influenza virus NS1 protein to model genome RNAs.</article-title>
<source><italic>J. Gen. Virol.</italic></source>
<volume>78</volume>(<issue>Pt 5</issue>), <fpage>1059</fpage>&#x02013;<lpage>1063</lpage>. <pub-id pub-id-type="doi">10.1099/0022-1317-78-5-1059</pub-id>
<?supplied-pmid 9152423?><pub-id pub-id-type="pmid">9152423</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatada</surname><given-names>E.</given-names></name><name><surname>Takizawa</surname><given-names>T.</given-names></name><name><surname>Fukuda</surname><given-names>R.</given-names></name></person-group> (<year>1992</year>). <article-title>Specific binding of influenza A virus NS1 protein to the virus minus-sense RNA in vitro.</article-title>
<source><italic>J. Gen. Virol.</italic></source>
<volume>73</volume>(<issue>Pt 1</issue>), <fpage>17</fpage>&#x02013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1099/0022-1317-73-1-17</pub-id>
<?supplied-pmid 1530962?><pub-id pub-id-type="pmid">1530962</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hengrung</surname><given-names>N.</given-names></name><name><surname>El Omari</surname><given-names>K.</given-names></name><name><surname>Serna Martin</surname><given-names>I.</given-names></name><name><surname>Vreede</surname><given-names>F. T.</given-names></name><name><surname>Cusack</surname><given-names>S.</given-names></name><name><surname>Rambo</surname><given-names>R. P.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Crystal structure of the RNA-dependent RNA polymerase from influenza C virus.</article-title>
<source><italic>Nature</italic></source>
<volume>527</volume>
<fpage>114</fpage>&#x02013;<lpage>117</lpage>. <pub-id pub-id-type="doi">10.1038/nature15525</pub-id>
<?supplied-pmid 26503046?><pub-id pub-id-type="pmid">26503046</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herfst</surname><given-names>S.</given-names></name><name><surname>Schrauwen</surname><given-names>E. J.</given-names></name><name><surname>Linster</surname><given-names>M.</given-names></name><name><surname>Chutinimitkul</surname><given-names>S.</given-names></name><name><surname>de Wit</surname><given-names>E.</given-names></name><name><surname>Munster</surname><given-names>V. J.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Airborne transmission of influenza A/H5N1 virus between ferrets.</article-title>
<source><italic>Science</italic></source>
<volume>336</volume>
<fpage>1534</fpage>&#x02013;<lpage>1541</lpage>. <pub-id pub-id-type="doi">10.1126/science.1213362</pub-id>
<?supplied-pmid 22723413?><pub-id pub-id-type="pmid">22723413</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwasaki</surname><given-names>A.</given-names></name><name><surname>Pillai</surname><given-names>P. S.</given-names></name></person-group> (<year>2014</year>). <article-title>Innate immunity to influenza virus infection.</article-title>
<source><italic>Nat. Rev. Immunol.</italic></source>
<volume>14</volume>
<fpage>315</fpage>&#x02013;<lpage>328</lpage>. <pub-id pub-id-type="doi">10.1038/nri3665</pub-id>
<?supplied-pmid 24762827?><pub-id pub-id-type="pmid">24762827</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimble</surname><given-names>J. B.</given-names></name><name><surname>Sorrell</surname><given-names>E.</given-names></name><name><surname>Shao</surname><given-names>H.</given-names></name><name><surname>Martin</surname><given-names>P. L.</given-names></name><name><surname>Perez</surname><given-names>D. R.</given-names></name></person-group> (<year>2011</year>). <article-title>Compatibility of H9N2 avian influenza surface genes and 2009 pandemic H1N1 internal genes for transmission in the ferret model.</article-title>
<source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source>
<volume>108</volume>
<fpage>12084</fpage>&#x02013;<lpage>12088</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1108058108</pub-id>
<?supplied-pmid 21730147?><pub-id pub-id-type="pmid">21730147</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kochs</surname><given-names>G.</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A.</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name></person-group> (<year>2007</year>). <article-title>Multiple anti-interferon actions of the influenza A virus NS1 protein.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>81</volume>
<fpage>7011</fpage>&#x02013;<lpage>7021</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02581-06</pub-id>
<?supplied-pmid 17442719?><pub-id pub-id-type="pmid">17442719</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kochs</surname><given-names>G.</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name><name><surname>Lienenklaus</surname><given-names>S.</given-names></name><name><surname>Weiss</surname><given-names>S.</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A.</given-names></name><name><surname>Staeheli</surname><given-names>P.</given-names></name></person-group> (<year>2009</year>). <article-title>Strong interferon-inducing capacity of a highly virulent variant of influenza A virus strain PR8 with deletions in the NS1 gene.</article-title>
<source><italic>J. Gen. Virol.</italic></source>
<volume>90</volume>(<issue>Pt 12</issue>), <fpage>2990</fpage>&#x02013;<lpage>2994</lpage>. <pub-id pub-id-type="doi">10.1099/vir.0.015727-0</pub-id>
<?supplied-pmid 19726611?><pub-id pub-id-type="pmid">19726611</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krammer</surname><given-names>F.</given-names></name><name><surname>Palese</surname><given-names>P.</given-names></name><name><surname>Steel</surname><given-names>J.</given-names></name></person-group> (<year>2015</year>). <article-title>Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin.</article-title>
<source><italic>Curr. Top. Microbiol. Immunol.</italic></source>
<volume>386</volume>
<fpage>301</fpage>&#x02013;<lpage>321</lpage>. <pub-id pub-id-type="doi">10.1007/82_2014_408</pub-id>
<?supplied-pmid 25007847?><pub-id pub-id-type="pmid">25007847</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamb</surname><given-names>R. A.</given-names></name><name><surname>Choppin</surname><given-names>P. W.</given-names></name><name><surname>Chanock</surname><given-names>R. M.</given-names></name><name><surname>Lai</surname><given-names>C. J.</given-names></name></person-group> (<year>1980</year>). <article-title>Mapping of the two overlapping genes for polypeptides NS1 and NS2 on RNA segment 8 of influenza virus genome.</article-title>
<source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source>
<volume>77</volume>
<fpage>1857</fpage>&#x02013;<lpage>1861</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.77.4.1857</pub-id>
<?supplied-pmid 6246509?><pub-id pub-id-type="pmid">6246509</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Min</surname><given-names>J. Y.</given-names></name><name><surname>Krug</surname><given-names>R. M.</given-names></name><name><surname>Sen</surname><given-names>G. C.</given-names></name></person-group> (<year>2006</year>). <article-title>Binding of the influenza A virus NS1 protein to PKR mediates the inhibition of its activation by either PACT or double-stranded RNA.</article-title>
<source><italic>Virology</italic></source>
<volume>349</volume>
<fpage>13</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2006.01.005</pub-id>
<?supplied-pmid 16466763?><pub-id pub-id-type="pmid">16466763</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname><given-names>K. J.</given-names></name><name><surname>Schmittgen</surname><given-names>T. D.</given-names></name></person-group> (<year>2001</year>). <article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.</article-title>
<source><italic>Methods</italic></source>
<volume>25</volume>
<fpage>402</fpage>&#x02013;<lpage>408</lpage>. <pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id>
<?supplied-pmid 11846609?><pub-id pub-id-type="pmid">11846609</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>J. S.</given-names></name><name><surname>Mistry</surname><given-names>B.</given-names></name><name><surname>Haslam</surname><given-names>S. M.</given-names></name><name><surname>Barclay</surname><given-names>W. S.</given-names></name></person-group> (<year>2019</year>). <article-title>Host and viral determinants of influenza A virus species specificity.</article-title>
<source><italic>Nat. Rev. Microbiol.</italic></source>
<volume>17</volume>
<fpage>67</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1038/s41579-018-0115-z</pub-id>
<?supplied-pmid 30487536?><pub-id pub-id-type="pmid">30487536</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Qian</surname><given-names>X. Y.</given-names></name><name><surname>Krug</surname><given-names>R. M.</given-names></name></person-group> (<year>1994</year>). <article-title>The influenza virus NS1 protein: a novel inhibitor of pre-mRNA splicing.</article-title>
<source><italic>Genes Dev.</italic></source>
<volume>8</volume>
<fpage>1817</fpage>&#x02013;<lpage>1828</lpage>. <pub-id pub-id-type="doi">10.1101/gad.8.15.1817</pub-id>
<?supplied-pmid 7958859?><pub-id pub-id-type="pmid">7958859</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manicassamy</surname><given-names>B.</given-names></name><name><surname>Manicassamy</surname><given-names>S.</given-names></name><name><surname>Belicha-Villanueva</surname><given-names>A.</given-names></name><name><surname>Pisanelli</surname><given-names>G.</given-names></name><name><surname>Pulendran</surname><given-names>B.</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A.</given-names></name></person-group> (<year>2010</year>). <article-title>Analysis of in vivo dynamics of influenza virus infection in mice using a GFP reporter virus.</article-title>
<source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source>
<volume>107</volume>
<fpage>11531</fpage>&#x02013;<lpage>11536</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.09149941070914994107</pub-id>
<?supplied-pmid 20534532?><pub-id pub-id-type="pmid">20534532</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marc</surname><given-names>D.</given-names></name></person-group> (<year>2014</year>). <article-title>Influenza virus non-structural protein NS1: interferon antagonism and beyond.</article-title>
<source><italic>J. Gen. Virol.</italic></source>
<volume>95</volume>(<issue>Pt 12</issue>), <fpage>2594</fpage>&#x02013;<lpage>2611</lpage>. <pub-id pub-id-type="doi">10.1099/vir.0.069542-0</pub-id>
<?supplied-pmid 25182164?><pub-id pub-id-type="pmid">25182164</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marion</surname><given-names>R. M.</given-names></name><name><surname>Zurcher</surname><given-names>T.</given-names></name><name><surname>de la Luna</surname><given-names>S.</given-names></name><name><surname>Ortin</surname><given-names>J.</given-names></name></person-group> (<year>1997</year>). <article-title>Influenza virus NS1 protein interacts with viral transcription-replication complexes in vivo.</article-title>
<source><italic>J. Gen. Virol.</italic></source>
<volume>78</volume>(<issue>Pt 10</issue>), <fpage>2447</fpage>&#x02013;<lpage>2451</lpage>. <pub-id pub-id-type="doi">10.1099/0022-1317-78-10-2447</pub-id>
<?supplied-pmid 9349463?><pub-id pub-id-type="pmid">9349463</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name><name><surname>Peersen</surname><given-names>O.</given-names></name><name><surname>Nogales</surname><given-names>A.</given-names></name></person-group> (<year>2018</year>). <article-title>Temperature sensitive mutations in influenza A viral ribonucleoprotein complex responsible for the attenuation of the live attenuated influenza vaccine.</article-title>
<source><italic>Viruses</italic></source>
<volume>10</volume>:<issue>E560</issue>. <pub-id pub-id-type="doi">10.3390/v10100560</pub-id>
<?supplied-pmid 30326610?><pub-id pub-id-type="pmid">30326610</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name><name><surname>Zuniga</surname><given-names>E. I.</given-names></name><name><surname>Rosario</surname><given-names>D.</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A.</given-names></name><name><surname>de la Torre</surname><given-names>J. C.</given-names></name></person-group> (<year>2006</year>). <article-title>Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>80</volume>
<fpage>9192</fpage>&#x02013;<lpage>9199</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00555-06</pub-id>
<?supplied-pmid 16940530?><pub-id pub-id-type="pmid">16940530</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuzaki</surname><given-names>Y.</given-names></name><name><surname>Sugawara</surname><given-names>K.</given-names></name><name><surname>Furuse</surname><given-names>Y.</given-names></name><name><surname>Shimotai</surname><given-names>Y.</given-names></name><name><surname>Hongo</surname><given-names>S.</given-names></name><name><surname>Oshitani</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Genetic lineage and reassortment of influenza C viruses circulating between 1947 and 2014.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>90</volume>
<fpage>8251</fpage>&#x02013;<lpage>8265</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00969-16</pub-id>
<?supplied-pmid 27384661?><pub-id pub-id-type="pmid">27384661</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mibayashi</surname><given-names>M.</given-names></name><name><surname>Mart&#x000ed;nez-Sobrido</surname><given-names>L.</given-names></name><name><surname>Loo</surname><given-names>Y. M.</given-names></name><name><surname>C&#x000e1;rdenas</surname><given-names>W. B.</given-names></name><name><surname>Gale</surname><given-names>M.</given-names><suffix>Jr</suffix></name><name><surname>Garc&#x000ed;a-Sastre</surname><given-names>A.</given-names></name></person-group> (<year>2007</year>). <article-title>Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>81</volume>
<fpage>514</fpage>&#x02013;<lpage>524</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01265-06</pub-id>
<?supplied-pmid 17079289?><pub-id pub-id-type="pmid">17079289</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monteagudo</surname><given-names>P. L.</given-names></name><name><surname>Munoz-Moreno</surname><given-names>R.</given-names></name><name><surname>Fribourg</surname><given-names>M.</given-names></name><name><surname>Potla</surname><given-names>U.</given-names></name><name><surname>Mena</surname><given-names>I.</given-names></name><name><surname>Marjanovic</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Differential modulation of innate immune responses in human primary cells by influenza A viruses carrying human or avian non-structural 1 proteins.</article-title>
<source><italic>J. Virol.</italic></source>
<pub-id pub-id-type="doi">10.1128/JVI.00999-19</pub-id>
<comment>[Epub ahead of print]</comment>. <?supplied-pmid 31597767?><pub-id pub-id-type="pmid">31597767</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrison</surname><given-names>J.</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A.</given-names></name></person-group> (<year>2014</year>). <article-title>STAT2 signaling and dengue virus infection.</article-title>
<source><italic>JAKSTAT</italic></source>
<volume>3</volume>:<issue>e27715</issue>. <pub-id pub-id-type="doi">10.4161/jkst.27715</pub-id>
<?supplied-pmid 24778924?><pub-id pub-id-type="pmid">24778924</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mostafa</surname><given-names>A.</given-names></name><name><surname>Abdelwhab</surname><given-names>E. M.</given-names></name><name><surname>Mettenleiter</surname><given-names>T. C.</given-names></name><name><surname>Pleschka</surname><given-names>S.</given-names></name></person-group> (<year>2018</year>). <article-title>Zoonotic potential of influenza A viruses: a comprehensive overview.</article-title>
<source><italic>Viruses</italic></source>
<volume>10</volume>:<issue>E497</issue>. <pub-id pub-id-type="doi">10.3390/v10090497</pub-id>
<?supplied-pmid 30217093?><pub-id pub-id-type="pmid">30217093</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mueller</surname><given-names>S. N.</given-names></name><name><surname>Langley</surname><given-names>W. A.</given-names></name><name><surname>Carnero</surname><given-names>E.</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A.</given-names></name><name><surname>Ahmed</surname><given-names>R.</given-names></name></person-group> (<year>2010</year>). <article-title>Immunization with live attenuated influenza viruses that express altered NS1 proteins results in potent and protective memory CD8+ T-cell responses.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>84</volume>
<fpage>1847</fpage>&#x02013;<lpage>1855</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01317-09JVI.01317-09</pub-id>
<?supplied-pmid 19939929?><pub-id pub-id-type="pmid">19939929</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munster</surname><given-names>V. J.</given-names></name><name><surname>de Wit</surname><given-names>E.</given-names></name><name><surname>van den Brand</surname><given-names>J. M.</given-names></name><name><surname>Herfst</surname><given-names>S.</given-names></name><name><surname>Schrauwen</surname><given-names>E. J.</given-names></name><name><surname>Bestebroer</surname><given-names>T. M.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets.</article-title>
<source><italic>Science</italic></source>
<volume>325</volume>
<fpage>481</fpage>&#x02013;<lpage>483</lpage>. <pub-id pub-id-type="doi">10.1126/science.1177127</pub-id>
<?supplied-pmid 19574348?><pub-id pub-id-type="pmid">19574348</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muraki</surname><given-names>Y.</given-names></name><name><surname>Furukawa</surname><given-names>T.</given-names></name><name><surname>Kohno</surname><given-names>Y.</given-names></name><name><surname>Matsuzaki</surname><given-names>Y.</given-names></name><name><surname>Takashita</surname><given-names>E.</given-names></name><name><surname>Sugawara</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Influenza C virus NS1 protein upregulates the splicing of viral mRNAs.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>84</volume>
<fpage>1957</fpage>&#x02013;<lpage>1966</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01627-09</pub-id>
<?supplied-pmid 20007279?><pub-id pub-id-type="pmid">20007279</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakada</surname><given-names>S.</given-names></name><name><surname>Graves</surname><given-names>P. N.</given-names></name><name><surname>Palese</surname><given-names>P.</given-names></name></person-group> (<year>1986</year>). <article-title>The influenza C virus NS gene: evidence for a spliced mRNA and a second NS gene product (NS2 protein).</article-title>
<source><italic>Virus Res.</italic></source>
<volume>4</volume>
<fpage>263</fpage>&#x02013;<lpage>273</lpage>. <pub-id pub-id-type="doi">10.1016/0168-1702(86)90005-5</pub-id>
<?supplied-pmid 2943090?><pub-id pub-id-type="pmid">2943090</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakatsu</surname><given-names>S.</given-names></name><name><surname>Murakami</surname><given-names>S.</given-names></name><name><surname>Shindo</surname><given-names>K.</given-names></name><name><surname>Horimoto</surname><given-names>T.</given-names></name><name><surname>Sagara</surname><given-names>H.</given-names></name><name><surname>Noda</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Influenza C and D viruses package eight organized ribonucleoprotein complexes.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>92</volume>:<issue>e02084-17</issue>. <pub-id pub-id-type="doi">10.1128/JVI.02084-17</pub-id>
<?supplied-pmid 29321324?><pub-id pub-id-type="pmid">29321324</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="book"><collab>National Research Council (U.S.) Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Institute for Laboratory Animal Research (U.S.), and National Academies Press (U.S.).</collab> (<year>2011</year>). <source><italic>Guide for the Care and Use of Laboratory Animals.</italic></source>
<publisher-loc>Washington, DC</publisher-loc>: <publisher-name>National Academies Press</publisher-name>.</mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nemeroff</surname><given-names>M. E.</given-names></name><name><surname>Barabino</surname><given-names>S. M.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Keller</surname><given-names>W.</given-names></name><name><surname>Krug</surname><given-names>R. M.</given-names></name></person-group> (<year>1998</year>). <article-title>Influenza virus NS1 protein interacts with the cellular 30 kDa subunit of CPSF and inhibits 3&#x02019;end formation of cellular pre-mRNAs.</article-title>
<source><italic>Mol. Cell</italic></source>
<volume>1</volume>
<fpage>991</fpage>&#x02013;<lpage>1000</lpage>. <pub-id pub-id-type="doi">10.1016/s1097-2765(00)80099-4</pub-id>
<?supplied-pmid 9651582?><pub-id pub-id-type="pmid">9651582</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nogales</surname><given-names>A.</given-names></name><name><surname>Baker</surname><given-names>S. F.</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name></person-group> (<year>2014a</year>). <article-title>Replication-competent influenza A viruses expressing a red fluorescent protein.</article-title>
<source><italic>Virology</italic></source>
<volume>476C</volume>
<fpage>206</fpage>&#x02013;<lpage>216</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2014.12.006</pub-id>
<?supplied-pmid 25553516?><pub-id pub-id-type="pmid">25553516</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nogales</surname><given-names>A.</given-names></name><name><surname>Baker</surname><given-names>S. F.</given-names></name><name><surname>Ortiz-Riano</surname><given-names>E.</given-names></name><name><surname>Dewhurst</surname><given-names>S.</given-names></name><name><surname>Topham</surname><given-names>D. J.</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name></person-group> (<year>2014b</year>). <article-title>Influenza A virus attenuation by codon deoptimization of the NS gene for vaccine development.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>88</volume>
<fpage>10525</fpage>&#x02013;<lpage>10540</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01565-14</pub-id>
<?supplied-pmid 24965472?><pub-id pub-id-type="pmid">24965472</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nogales</surname><given-names>A.</given-names></name><name><surname>Chauche</surname><given-names>C.</given-names></name><name><surname>DeDiego</surname><given-names>M. L.</given-names></name><name><surname>Topham</surname><given-names>D. J.</given-names></name><name><surname>Parrish</surname><given-names>C. R.</given-names></name><name><surname>Murcia</surname><given-names>P. R.</given-names></name><etal/></person-group> (<year>2017a</year>). <article-title>The K186E amino acid substitution in the canine influenza virus H3N8 NS1 protein restores its ability to inhibit host gene expression.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>91</volume>:<issue>e00877-17</issue>. <pub-id pub-id-type="doi">10.1128/JVI.00877-17</pub-id>
<?supplied-pmid 28835506?><pub-id pub-id-type="pmid">28835506</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nogales</surname><given-names>A.</given-names></name><name><surname>Huang</surname><given-names>K.</given-names></name><name><surname>Chauche</surname><given-names>C.</given-names></name><name><surname>DeDiego</surname><given-names>M. L.</given-names></name><name><surname>Murcia</surname><given-names>P. R.</given-names></name><name><surname>Parrish</surname><given-names>C. R.</given-names></name><etal/></person-group> (<year>2017b</year>). <article-title>Canine influenza viruses with modified NS1 proteins for the development of live-attenuated vaccines.</article-title>
<source><italic>Virology</italic></source>
<volume>500</volume>
<fpage>1</fpage>&#x02013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2016.10.008</pub-id>
<?supplied-pmid 27750071?><pub-id pub-id-type="pmid">27750071</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nogales</surname><given-names>A.</given-names></name><name><surname>Perez</surname><given-names>D. R.</given-names></name><name><surname>Santos</surname><given-names>J.</given-names></name><name><surname>Finch</surname><given-names>C.</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name></person-group> (<year>2017c</year>). <article-title>Reverse genetics of influenza B viruses.</article-title>
<source><italic>Methods Mol. Biol.</italic></source>
<volume>1602</volume>
<fpage>205</fpage>&#x02013;<lpage>238</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4939-6964-7_14</pub-id>
<?supplied-pmid 28508223?><pub-id pub-id-type="pmid">28508223</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nogales</surname><given-names>A.</given-names></name><name><surname>Rodriguez</surname><given-names>L.</given-names></name><name><surname>DeDiego</surname><given-names>M. L.</given-names></name><name><surname>Topham</surname><given-names>D. J.</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name></person-group> (<year>2017d</year>). <article-title>Interplay of PA-X and NS1 proteins in replication and pathogenesis of a temperature-sensitive 2009 pandemic H1N1 influenza A virus.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>91</volume>:<issue>e00720-17</issue>. <pub-id pub-id-type="doi">10.1128/JVI.00720-17</pub-id>
<?supplied-pmid 28637750?><pub-id pub-id-type="pmid">28637750</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nogales</surname><given-names>A.</given-names></name><name><surname>DeDiego</surname><given-names>M. L.</given-names></name><name><surname>Topham</surname><given-names>D. J.</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name></person-group> (<year>2016a</year>). <article-title>Rearrangement of influenza virus spliced segments for the development of live-attenuated vaccines.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>90</volume>
<fpage>6291</fpage>&#x02013;<lpage>6302</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00410-16</pub-id>
<?supplied-pmid 27122587?><pub-id pub-id-type="pmid">27122587</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nogales</surname><given-names>A.</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name><name><surname>Topham</surname><given-names>D. J.</given-names></name><name><surname>DeDiego</surname><given-names>M. L.</given-names></name></person-group> (<year>2016b</year>). <article-title>NS1 protein amino acid changes D189N and V194I affect interferon responses, thermosensitivity and virulence of circulating H3N2 human influenza A viruses.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>91</volume>:<issue>e01930-16</issue>. <pub-id pub-id-type="doi">10.1128/JVI.01930-16</pub-id>
<?supplied-pmid 28003482?><pub-id pub-id-type="pmid">28003482</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nogales</surname><given-names>A.</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name></person-group> (<year>2016</year>). <article-title>Reverse genetics approaches for the development of influenza vaccines.</article-title>
<source><italic>Int. J. Mol. Sci.</italic></source>
<volume>18</volume>:<issue>E20</issue>. <pub-id pub-id-type="doi">10.3390/ijms18010020</pub-id>
<?supplied-pmid 28025504?><pub-id pub-id-type="pmid">28025504</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nogales</surname><given-names>A.</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name><name><surname>Chiem</surname><given-names>K.</given-names></name><name><surname>Topham</surname><given-names>D. J.</given-names></name><name><surname>DeDiego</surname><given-names>M. L.</given-names></name></person-group> (<year>2018a</year>). <article-title>Functional evolution of the 2009 pandemic H1N1 influenza virus NS1 and PA in humans.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>92</volume>:<issue>e01206-18</issue>. <pub-id pub-id-type="doi">10.1128/JVI.01206-18</pub-id>
<?supplied-pmid 30021892?><pub-id pub-id-type="pmid">30021892</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nogales</surname><given-names>A.</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name><name><surname>Topham</surname><given-names>D. J.</given-names></name><name><surname>DeDiego</surname><given-names>M. L.</given-names></name></person-group> (<year>2018b</year>). <article-title>Modulation of innate immune responses by the influenza A NS1 and PA-X proteins.</article-title>
<source><italic>Viruses</italic></source>
<volume>10</volume>:<issue>E708</issue>. <pub-id pub-id-type="doi">10.3390/v10120708</pub-id>
<?supplied-pmid 30545063?><pub-id pub-id-type="pmid">30545063</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nogales</surname><given-names>A.</given-names></name><name><surname>Piepenbrink</surname><given-names>M. S.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Ortega</surname><given-names>S.</given-names></name><name><surname>Basu</surname><given-names>M.</given-names></name><name><surname>Fucile</surname><given-names>C. F.</given-names></name><etal/></person-group> (<year>2018c</year>). <article-title>A highly potent and broadly neutralizing H1 influenza-specific human monoclonal antibody.</article-title>
<source><italic>Sci. Rep.</italic></source>
<volume>8</volume>:<issue>4374</issue>. <pub-id pub-id-type="doi">10.1038/s41598-018-22307-8</pub-id>
<?supplied-pmid 29531320?><pub-id pub-id-type="pmid">29531320</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nogales</surname><given-names>A.</given-names></name><name><surname>Rodriguez-Sanchez</surname><given-names>I.</given-names></name><name><surname>Monte</surname><given-names>K.</given-names></name><name><surname>Lenschow</surname><given-names>D. J.</given-names></name><name><surname>Perez</surname><given-names>D. R.</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name></person-group> (<year>2015</year>). <article-title>Replication-competent fluorescent-expressing influenza B virus.</article-title>
<source><italic>Virus Res.</italic></source>
<volume>213</volume>
<fpage>69</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2015.11.014</pub-id>
<?supplied-pmid 26590325?><pub-id pub-id-type="pmid">26590325</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Opitz</surname><given-names>B.</given-names></name><name><surname>Rejaibi</surname><given-names>A.</given-names></name><name><surname>Dauber</surname><given-names>B.</given-names></name><name><surname>Eckhard</surname><given-names>J.</given-names></name><name><surname>Vinzing</surname><given-names>M.</given-names></name><name><surname>Schmeck</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>IFNbeta induction by influenza A virus is mediated by RIG-I which is regulated by the viral NS1 protein.</article-title>
<source><italic>Cell Microbiol.</italic></source>
<volume>9</volume>
<fpage>930</fpage>&#x02013;<lpage>938</lpage>. <pub-id pub-id-type="doi">10.1111/j.1462-5822.2006.00841.x</pub-id>
<?supplied-pmid 17140406?><pub-id pub-id-type="pmid">17140406</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osterhaus</surname><given-names>A. D.</given-names></name><name><surname>Rimmelzwaan</surname><given-names>G. F.</given-names></name><name><surname>Martina</surname><given-names>B. E.</given-names></name><name><surname>Bestebroer</surname><given-names>T. M.</given-names></name><name><surname>Fouchier</surname><given-names>R. A.</given-names></name></person-group> (<year>2000</year>). <article-title>Influenza B virus in seals.</article-title>
<source><italic>Science</italic></source>
<volume>288</volume>
<fpage>1051</fpage>&#x02013;<lpage>1053</lpage>. <pub-id pub-id-type="doi">10.1126/science.288.5468.1051</pub-id>
<?supplied-pmid 10807575?><pub-id pub-id-type="pmid">10807575</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pachler</surname><given-names>K.</given-names></name><name><surname>Vlasak</surname><given-names>R.</given-names></name></person-group> (<year>2011</year>). <article-title>Influenza C virus NS1 protein counteracts RIG-I-mediated IFN signalling.</article-title>
<source><italic>Virol. J.</italic></source>
<volume>8</volume>:<issue>48</issue>. <pub-id pub-id-type="doi">10.1186/1743-422X-8-48</pub-id>
<?supplied-pmid 21288362?><pub-id pub-id-type="pmid">21288362</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>M. S.</given-names></name><name><surname>Shaw</surname><given-names>M. L.</given-names></name><name><surname>Munoz-Jordan</surname><given-names>J.</given-names></name><name><surname>Cros</surname><given-names>J. F.</given-names></name><name><surname>Nakaya</surname><given-names>T.</given-names></name><name><surname>Bouvier</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>77</volume>
<fpage>1501</fpage>&#x02013;<lpage>1511</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.77.2.1501-1511.2003</pub-id>
<?supplied-pmid 12502864?><pub-id pub-id-type="pmid">12502864</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parrish</surname><given-names>C. R.</given-names></name><name><surname>Murcia</surname><given-names>P. R.</given-names></name><name><surname>Holmes</surname><given-names>E. C.</given-names></name></person-group> (<year>2015</year>). <article-title>Influenza virus reservoirs and intermediate hosts: dogs, horses, and new possibilities for influenza virus exposure of humans.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>89</volume>
<fpage>2990</fpage>&#x02013;<lpage>2994</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.03146-14</pub-id>
<?supplied-pmid 25540375?><pub-id pub-id-type="pmid">25540375</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patzina</surname><given-names>C.</given-names></name><name><surname>Botting</surname><given-names>C. H.</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A.</given-names></name><name><surname>Randall</surname><given-names>R. E.</given-names></name><name><surname>Hale</surname><given-names>B. G.</given-names></name></person-group> (<year>2017</year>). <article-title>Human interactome of the influenza B virus NS1 protein.</article-title>
<source><italic>J. Gen. Virol.</italic></source>
<volume>98</volume>
<fpage>2267</fpage>&#x02013;<lpage>2273</lpage>. <pub-id pub-id-type="doi">10.1099/jgv.0.000909</pub-id>
<?supplied-pmid 28869005?><pub-id pub-id-type="pmid">28869005</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paules</surname><given-names>C. I.</given-names></name><name><surname>Sullivan</surname><given-names>S. G.</given-names></name><name><surname>Subbarao</surname><given-names>K.</given-names></name><name><surname>Fauci</surname><given-names>A. S.</given-names></name></person-group> (<year>2018</year>). <article-title>Chasing seasonal influenza - the need for a universal influenza vaccine.</article-title>
<source><italic>N. Engl. J. Med.</italic></source>
<volume>378</volume>
<fpage>7</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMp1714916</pub-id>
<?supplied-pmid 29185857?><pub-id pub-id-type="pmid">29185857</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pica</surname><given-names>N.</given-names></name><name><surname>Langlois</surname><given-names>R. A.</given-names></name><name><surname>Krammer</surname><given-names>F.</given-names></name><name><surname>Margine</surname><given-names>I.</given-names></name><name><surname>Palese</surname><given-names>P.</given-names></name></person-group> (<year>2012</year>). <article-title>NS1-truncated live attenuated virus vaccine provides robust protection to aged mice from viral challenge.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>86</volume>
<fpage>10293</fpage>&#x02013;<lpage>10301</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01131-12</pub-id>
<?supplied-pmid 22787224?><pub-id pub-id-type="pmid">22787224</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piepenbrink</surname><given-names>M. S.</given-names></name><name><surname>Nogales</surname><given-names>A.</given-names></name><name><surname>Basu</surname><given-names>M.</given-names></name><name><surname>Fucile</surname><given-names>C. F.</given-names></name><name><surname>Liesveld</surname><given-names>J. L.</given-names></name><name><surname>Keefer</surname><given-names>M. C.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Broad and protective influenza B virus neuraminidase antibodies in humans after vaccination and their clonal persistence as plasma cells.</article-title>
<source><italic>mBio</italic></source>
<volume>10</volume>:<issue>e00066-19</issue>. <pub-id pub-id-type="doi">10.1128/mBio.00066-19</pub-id>
<?supplied-pmid 30862743?><pub-id pub-id-type="pmid">30862743</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>Y.</given-names></name><name><surname>Krug</surname><given-names>R. M.</given-names></name></person-group> (<year>1994</year>). <article-title>The influenza virus NS1 protein is a poly(A)-binding protein that inhibits nuclear export of mRNAs containing poly(A).</article-title>
<source><italic>J. Virol.</italic></source>
<volume>68</volume>
<fpage>2425</fpage>&#x02013;<lpage>2432</lpage>.<pub-id pub-id-type="pmid">7908060</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>Y.</given-names></name><name><surname>Nemeroff</surname><given-names>M.</given-names></name><name><surname>Krug</surname><given-names>R. M.</given-names></name></person-group> (<year>1995</year>). <article-title>The influenza virus NS1 protein binds to a specific region in human U6 snRNA and inhibits U6-U2 and U6-U4 snRNA interactions during splicing.</article-title>
<source><italic>RNA</italic></source>
<volume>1</volume>
<fpage>304</fpage>&#x02013;<lpage>316</lpage>. <?supplied-pmid 7489502?><pub-id pub-id-type="pmid">7489502</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Randall</surname><given-names>R. E.</given-names></name><name><surname>Goodbourn</surname><given-names>S.</given-names></name></person-group> (<year>2008</year>). <article-title>Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures.</article-title>
<source><italic>J. Gen. Virol.</italic></source>
<volume>89</volume>(<issue>Pt 1</issue>), <fpage>1</fpage>&#x02013;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1099/vir.0.83391-0</pub-id>
<?supplied-pmid 18089727?><pub-id pub-id-type="pmid">18089727</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raviotta</surname><given-names>J. M.</given-names></name><name><surname>Smith</surname><given-names>K. J.</given-names></name><name><surname>DePasse</surname><given-names>J.</given-names></name><name><surname>Brown</surname><given-names>S. T.</given-names></name><name><surname>Shim</surname><given-names>E.</given-names></name><name><surname>Nowalk</surname><given-names>M. P.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Cost-effectiveness and public health impact of alternative influenza vaccination strategies in high-risk adults.</article-title>
<source><italic>Vaccine</italic></source>
<volume>35</volume>
<fpage>5708</fpage>&#x02013;<lpage>5713</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2017.07.069</pub-id>
<?supplied-pmid 28890196?><pub-id pub-id-type="pmid">28890196</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richt</surname><given-names>J. A.</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A.</given-names></name></person-group> (<year>2009</year>). <article-title>Attenuated influenza virus vaccines with modified NS1 proteins.</article-title>
<source><italic>Curr. Top. Microbiol. Immunol.</italic></source>
<volume>333</volume>
<fpage>177</fpage>&#x02013;<lpage>195</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-540-92165-3_9</pub-id>
<?supplied-pmid 19768406?><pub-id pub-id-type="pmid">19768406</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robb</surname><given-names>N. C.</given-names></name><name><surname>Chase</surname><given-names>G.</given-names></name><name><surname>Bier</surname><given-names>K.</given-names></name><name><surname>Vreede</surname><given-names>F. T.</given-names></name><name><surname>Shaw</surname><given-names>P. C.</given-names></name><name><surname>Naffakh</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>The influenza A virus NS1 protein interacts with the nucleoprotein of viral ribonucleoprotein complexes.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>85</volume>
<fpage>5228</fpage>&#x02013;<lpage>5231</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02562-10JVI.02562-10</pub-id>
<?supplied-pmid 21411538?><pub-id pub-id-type="pmid">21411538</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robb</surname><given-names>N. C.</given-names></name><name><surname>Jackson</surname><given-names>D.</given-names></name><name><surname>Vreede</surname><given-names>F. T.</given-names></name><name><surname>Fodor</surname><given-names>E.</given-names></name></person-group> (<year>2010</year>). <article-title>Splicing of influenza A virus NS1 mRNA is independent of the viral NS1 protein.</article-title>
<source><italic>J. Gen. Virol.</italic></source>
<volume>91</volume>(<issue>Pt 9</issue>), <fpage>2331</fpage>&#x02013;<lpage>2340</lpage>. <pub-id pub-id-type="doi">10.1099/vir.0.022004-0</pub-id>
<?supplied-pmid 20519456?><pub-id pub-id-type="pmid">20519456</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>L.</given-names></name><name><surname>Nogales</surname><given-names>A.</given-names></name><name><surname>Iqbal</surname><given-names>M.</given-names></name><name><surname>Perez</surname><given-names>D. R.</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name></person-group> (<year>2018</year>). <article-title>Identification of amino acid residues responsible for inhibition of host gene expression by influenza A H9N2 NS1 targeting of CPSF30.</article-title>
<source><italic>Front. Microbiol.</italic></source>
<volume>9</volume>:<issue>2546</issue>. <pub-id pub-id-type="doi">10.3389/fmicb.2018.02546</pub-id>
<?supplied-pmid 30405591?><pub-id pub-id-type="pmid">30405591</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>L.</given-names></name><name><surname>Nogales</surname><given-names>A.</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name></person-group> (<year>2017</year>). <article-title>Influenza A virus studies in a mouse model of infection.</article-title>
<source><italic>J. Vis. Exp</italic>.</source>
<volume>127</volume>:<issue>55898</issue>. <pub-id pub-id-type="doi">10.3791/55898</pub-id>
<?supplied-pmid 28930978?><pub-id pub-id-type="pmid">28930978</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seibert</surname><given-names>C. W.</given-names></name><name><surname>Kaminski</surname><given-names>M.</given-names></name><name><surname>Philipp</surname><given-names>J.</given-names></name><name><surname>Rubbenstroth</surname><given-names>D.</given-names></name><name><surname>Albrecht</surname><given-names>R. A.</given-names></name><name><surname>Schwalm</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>84</volume>
<fpage>11219</fpage>&#x02013;<lpage>11226</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01424-10</pub-id>
<?supplied-pmid 20739532?><pub-id pub-id-type="pmid">20739532</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spesock</surname><given-names>A.</given-names></name><name><surname>Malur</surname><given-names>M.</given-names></name><name><surname>Hossain</surname><given-names>M. J.</given-names></name><name><surname>Chen</surname><given-names>L. M.</given-names></name><name><surname>Njaa</surname><given-names>B. L.</given-names></name><name><surname>Davis</surname><given-names>C. T.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>The virulence of 1997 H5N1 influenza viruses in the mouse model is increased by correcting a defect in their NS1 proteins.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>85</volume>
<fpage>7048</fpage>&#x02013;<lpage>7058</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00417-11JVI.00417-11</pub-id>
<?supplied-pmid 21593152?><pub-id pub-id-type="pmid">21593152</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steel</surname><given-names>J.</given-names></name><name><surname>Lowen</surname><given-names>A. C.</given-names></name><name><surname>Mubareka</surname><given-names>S.</given-names></name><name><surname>Palese</surname><given-names>P.</given-names></name></person-group> (<year>2009a</year>). <article-title>Transmission of influenza virus in a mammalian host is increased by PB2 amino acids 627K or 627E/701N.</article-title>
<source><italic>PLoS Pathog.</italic></source>
<volume>5</volume>:<issue>e1000252</issue>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1000252</pub-id>
<?supplied-pmid 19119420?><pub-id pub-id-type="pmid">19119420</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steel</surname><given-names>J.</given-names></name><name><surname>Lowen</surname><given-names>A. C.</given-names></name><name><surname>Pena</surname><given-names>L.</given-names></name><name><surname>Angel</surname><given-names>M.</given-names></name><name><surname>Solorzano</surname><given-names>A.</given-names></name><name><surname>Albrecht</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2009b</year>). <article-title>Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>83</volume>
<fpage>1742</fpage>&#x02013;<lpage>1753</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01920-08</pub-id>
<?supplied-pmid 19073731?><pub-id pub-id-type="pmid">19073731</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steidle</surname><given-names>S.</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name><name><surname>Mordstein</surname><given-names>M.</given-names></name><name><surname>Lienenklaus</surname><given-names>S.</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A.</given-names></name><name><surname>Staheli</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Glycine 184 in nonstructural protein NS1 determines the virulence of influenza A virus strain PR8 without affecting the host interferon response.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>84</volume>
<fpage>12761</fpage>&#x02013;<lpage>12770</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00701-10</pub-id>
<?supplied-pmid 20926573?><pub-id pub-id-type="pmid">20926573</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>S.</given-names></name><name><surname>Fu</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Kerlin</surname><given-names>F.</given-names></name><name><surname>Veit</surname><given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>Novel influenza D virus: epidemiology, pathology, evolution and biological characteristics.</article-title>
<source><italic>Virulence</italic></source>
<volume>8</volume>
<fpage>1580</fpage>&#x02013;<lpage>1591</lpage>. <pub-id pub-id-type="doi">10.1080/21505594.2017.1365216</pub-id>
<?supplied-pmid 28812422?><pub-id pub-id-type="pmid">28812422</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talon</surname><given-names>J.</given-names></name><name><surname>Salvatore</surname><given-names>M.</given-names></name><name><surname>O&#x02019;Neill</surname><given-names>R. E.</given-names></name><name><surname>Nakaya</surname><given-names>Y.</given-names></name><name><surname>Zheng</surname><given-names>H.</given-names></name><name><surname>Muster</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2000</year>). <article-title>Influenza A and B viruses expressing altered NS1 proteins: a vaccine approach.</article-title>
<source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source>
<volume>97</volume>
<fpage>4309</fpage>&#x02013;<lpage>4314</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.070525997</pub-id>
<?supplied-pmid 10725408?><pub-id pub-id-type="pmid">10725408</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terrier</surname><given-names>O.</given-names></name><name><surname>Textoris</surname><given-names>J.</given-names></name><name><surname>Carron</surname><given-names>C.</given-names></name><name><surname>Marcel</surname><given-names>V.</given-names></name><name><surname>Bourdon</surname><given-names>J. C.</given-names></name><name><surname>Rosa-Calatrava</surname><given-names>M.</given-names></name></person-group> (<year>2013</year>). <article-title>Host microRNA molecular signatures associated with human H1N1 and H3N2 influenza A viruses reveal an unanticipated antiviral activity for miR-146a.</article-title>
<source><italic>J. Gen. Virol.</italic></source>
<volume>94</volume>(<issue>Pt 5</issue>), <fpage>985</fpage>&#x02013;<lpage>995</lpage>. <pub-id pub-id-type="doi">10.1099/vir.0.049528-0vir.0.049528-0</pub-id>
<?supplied-pmid 23343627?><pub-id pub-id-type="pmid">23343627</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>S.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Shi</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Bourgeois</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>New world bats harbor diverse influenza A viruses.</article-title>
<source><italic>PLoS Pathog.</italic></source>
<volume>9</volume>:<issue>e1003657</issue>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1003657</pub-id>
<?supplied-pmid 24130481?><pub-id pub-id-type="pmid">24130481</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turkington</surname><given-names>H. L.</given-names></name><name><surname>Juozapaitis</surname><given-names>M.</given-names></name><name><surname>Kerry</surname><given-names>P. S.</given-names></name><name><surname>Aydillo</surname><given-names>T.</given-names></name><name><surname>Ayllon</surname><given-names>J.</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Novel bat influenza virus NS1 proteins bind double-stranded RNA and antagonize host innate immunity.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>89</volume>
<fpage>10696</fpage>&#x02013;<lpage>10701</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01430-15JVI.01430-15</pub-id>
<?supplied-pmid 26246567?><pub-id pub-id-type="pmid">26246567</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turkington</surname><given-names>H. L.</given-names></name><name><surname>Juozapaitis</surname><given-names>M.</given-names></name><name><surname>Tsolakos</surname><given-names>N.</given-names></name><name><surname>Corrales-Aguilar</surname><given-names>E.</given-names></name><name><surname>Schwemmle</surname><given-names>M.</given-names></name><name><surname>Hale</surname><given-names>B. G.</given-names></name></person-group> (<year>2018</year>). <article-title>Unexpected functional divergence of bat influenza virus NS1 proteins.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>92</volume>:<issue>e02097-17</issue>. <pub-id pub-id-type="doi">10.1128/JVI.02097-17</pub-id>
<?supplied-pmid 29237829?><pub-id pub-id-type="pmid">29237829</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Twu</surname><given-names>K. Y.</given-names></name><name><surname>Noah</surname><given-names>D. L.</given-names></name><name><surname>Rao</surname><given-names>P.</given-names></name><name><surname>Kuo</surname><given-names>R. L.</given-names></name><name><surname>Krug</surname><given-names>R. M.</given-names></name></person-group> (<year>2006</year>). <article-title>The CPSF30 binding site on the NS1A protein of influenza A virus is a potential antiviral target.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>80</volume>
<fpage>3957</fpage>&#x02013;<lpage>3965</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.80.8.3957-3965.2006</pub-id>
<?supplied-pmid 16571812?><pub-id pub-id-type="pmid">16571812</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uccellini</surname><given-names>M. B.</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A.</given-names></name></person-group> (<year>2018</year>). <article-title>ISRE-reporter mouse reveals high basal and induced type I IFN responses in inflammatory monocytes.</article-title>
<source><italic>Cell Rep.</italic></source>
<volume>25</volume>
<fpage>2784.e3</fpage>&#x02013;<lpage>2796.e3</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2018.11.030</pub-id>
<?supplied-pmid 30517866?><pub-id pub-id-type="pmid">30517866</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J. P.</given-names></name><name><surname>Kurt-Jones</surname><given-names>E. A.</given-names></name><name><surname>Finberg</surname><given-names>R. W.</given-names></name></person-group> (<year>2007</year>). <article-title>Innate immunity to respiratory viruses.</article-title>
<source><italic>Cell Microbiol.</italic></source>
<volume>9</volume>
<fpage>1641</fpage>&#x02013;<lpage>1646</lpage>. <pub-id pub-id-type="doi">10.1111/j.1462-5822.2007.00961.x</pub-id>
<?supplied-pmid 17506818?><pub-id pub-id-type="pmid">17506818</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Ludwig</surname><given-names>K.</given-names></name><name><surname>Bottcher</surname><given-names>C.</given-names></name><name><surname>Veit</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>The role of stearate attachment to the hemagglutinin-esterase-fusion glycoprotein HEF of influenza C virus.</article-title>
<source><italic>Cell Microbiol.</italic></source>
<volume>18</volume>
<fpage>692</fpage>&#x02013;<lpage>704</lpage>. <pub-id pub-id-type="doi">10.1111/cmi.12541</pub-id>
<?supplied-pmid 26518983?><pub-id pub-id-type="pmid">26518983</pub-id></mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Krug</surname><given-names>R. M.</given-names></name></person-group> (<year>1998</year>). <article-title>U6atac snRNA, the highly divergent counterpart of U6 snRNA, is the specific target that mediates inhibition of AT-AC splicing by the influenza virus NS1 protein.</article-title>
<source><italic>RNA</italic></source>
<volume>4</volume>
<fpage>55</fpage>&#x02013;<lpage>64</lpage>. <?supplied-pmid 9436908?><pub-id pub-id-type="pmid">9436908</pub-id></mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wanitchang</surname><given-names>A.</given-names></name><name><surname>Narkpuk</surname><given-names>J.</given-names></name><name><surname>Jaru-ampornpan</surname><given-names>P.</given-names></name><name><surname>Jengarn</surname><given-names>J.</given-names></name><name><surname>Jongkaewwattana</surname><given-names>A.</given-names></name></person-group> (<year>2012</year>). <article-title>Inhibition of influenza A virus replication by influenza B virus nucleoprotein: an insight into interference between influenza A and B viruses.</article-title>
<source><italic>Virology</italic></source>
<volume>432</volume>
<fpage>194</fpage>&#x02013;<lpage>203</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2012.06.016</pub-id>
<?supplied-pmid 22770925?><pub-id pub-id-type="pmid">22770925</pub-id></mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>T.</given-names></name><name><surname>Kawaoka</surname><given-names>Y.</given-names></name></person-group> (<year>2015</year>). <article-title>Influenza virus-host interactomes as a basis for antiviral drug development.</article-title>
<source><italic>Curr. Opin. Virol.</italic></source>
<volume>14</volume>
<fpage>71</fpage>&#x02013;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1016/j.coviro.2015.08.008</pub-id>
<?supplied-pmid 26364134?><pub-id pub-id-type="pmid">26364134</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>P. F.</given-names></name><name><surname>Neumann</surname><given-names>G.</given-names></name><name><surname>Kawaoka</surname><given-names>Y.</given-names></name></person-group> (<year>2007</year>). &#x0201c;<article-title>Orthomyxoviruses</article-title>,&#x0201d; in <source><italic>Fields Virology</italic></source>, <edition>5th Edn</edition>, <role>eds</role>
<person-group person-group-type="editor"><name><surname>Knipe</surname><given-names>D. M.</given-names></name><name><surname>Howley</surname><given-names>P. M.</given-names></name><name><surname>Griffin</surname><given-names>D. E.</given-names></name><name><surname>Lamb</surname><given-names>R. A.</given-names></name><name><surname>Martin</surname><given-names>M. A.</given-names></name></person-group> (<publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>Lippincott Williams and WIlkins</publisher-name>).</mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>S. W.</given-names></name><name><surname>Webby</surname><given-names>R. J.</given-names></name><name><surname>Webster</surname><given-names>R. G.</given-names></name></person-group> (<year>2014</year>). <article-title>Evolution and ecology of influenza a viruses.</article-title>
<source><italic>Curr. Top. Microbiol. Immunol.</italic></source>
<volume>385</volume>
<fpage>359</fpage>&#x02013;<lpage>375</lpage>. <pub-id pub-id-type="doi">10.1007/82_2014_396</pub-id>
<?supplied-pmid 24990620?><pub-id pub-id-type="pmid">24990620</pub-id></mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>W.</given-names></name><name><surname>Krug</surname><given-names>R. M.</given-names></name></person-group> (<year>2001</year>). <article-title>Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein.</article-title>
<source><italic>EMBO J.</italic></source>
<volume>20</volume>
<fpage>362</fpage>&#x02013;<lpage>371</lpage>. <pub-id pub-id-type="doi">10.1093/emboj/20.3.362</pub-id>
<?supplied-pmid 11157743?><pub-id pub-id-type="pmid">11157743</pub-id></mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>He</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Wen</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Genetic evolution and molecular selection of the HE gene of influenza C virus.</article-title>
<source><italic>Viruses</italic></source>
<volume>11</volume>:<issue>E167</issue>. <pub-id pub-id-type="doi">10.3390/v11020167</pub-id>
<?supplied-pmid 30791465?><pub-id pub-id-type="pmid">30791465</pub-id></mixed-citation></ref></ref-list></back></article>